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Abstract
Alzheimer’s disease (AD) is a fatal disorder with no apparent cure. Early-onset AD
(EOAD) occurs in individuals before the age of 65, and late-onset AD (LOAD) occurs in
individuals age 65 and older. Past studies have proven that AD is fatal among Americans
age 65 and older. The disease is characterized by impairments in memory and executive
function as well as other cognitive and behavioral problems. The research questions
addressed by this sequential, mixed-method study compared EOAD and LOAD by
exploring common behavioral/cognitive symptoms and stage levels of AD. Research
participants were recruited from the Alzheimer’s Association who were members of
caregiver support groups and cared for an individual with AD. The qualitative component
of this study consisted of a qualitative interview given to caregivers (N = 6), which was
audio-recorded and transcribed verbatim using the 6-phase thematic analysis.
Sequentially, the quantitative component of this study consisted of the BEHAVE-AD and
Short IQCODE instruments, which were filled out and completed by caregivers (N = 20)
on behalf of patients with probable AD. These data were analyzed using 1-way ANOVA,
with the alpha set at 0.05. Integration of qualitative and quantitative results indicated no
differences in cognitive or behavioral symptoms of either EOAD or LOAD care
recipients. These findings have implications for positive social change by continually
involving caregiver participants in future studies. Doing so can ensure that care
recipients, whether they have been diagnosed at EOAD or LOAD, have a voice.
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Chapter 1: Introduction to the Study
Introduction
Alzheimer’s disease (AD) is the sixth leading cause of death in the United States
(Alzheimer’s Association, 2016). AD is also the fifth leading cause of death among
Americans age 65 and older. Approximately 5.4 million Americans suffer from this
neurodegenerative disease (AA, 2016). The financial and medical cost to treat AD is
between $200 and $600 billion, annually. The average age of diagnosis is 65 (Duke
University Medical Center, 2002). In the next decade there will be 10 million more
individuals diagnosed with AD due to the baby boomer generation—those born between
1946 and 1964—turning 65 and older. By the year 2050, the annual cost to treat this
population will increase to well over $1 trillion (Okie, 2011). Diagnosis of AD increases
significantly with age. The Alzheimer’s Association Report (2012) indicated that there
are about 53 new cases per 1000 individuals aged 65 to 74 years, 170 new cases per 1000
individuals aged 75 to 84 years, and 231 cases per 1000 individuals 85 and older (the
oldest old).
According to the Alzheimer’s Association (2012), aging baby boomers will
increase the percentage of Americans living longer and being amongst the oldest old (85
and older). Therefore, this increases their chances of developing AD. Age is a consistent
risk factor for AD (Kalaria et al., 2008). The oldest baby boomer turned 65 years old in
2011 and the youngest baby boomer will turn 65 years old in 2029. The Centers for
Disease Control and Prevention and the U.S. Census Bureau estimate that by 2030, those
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aged 65 and older will double in population and these 71 million “older” Americans will
account for 20% of the entire population (AA, 2012).
Background
Alzheimer’s disease (AD) is a neurodegenerative brain disorder of unknown
cause with neuropathological and neurochemical features. The disorder is usually
harmful in onset and increases slowly, but steadily, over a period of several years
(Jongbloed et al., 2013). Once individuals have been diagnosed with AD, they can live
with the disease, on average, 4 to 8 years before death (AA, 2013). However, there are
those who may live as long as 20 years after being diagnosed with AD.
A significant number of researchers and scientists are in agreement that vital
processes are interrupted by amyloid plaques and neurofibrillary tangles, which are
considered to be the two hallmarks of AD (Braak & Tredici, 2012; Cummings, Golde,
Sano, & Tariot, 2007; Jongbloed et al., 2013; Kar et al., 2004; Yu et al., 2013). The role
these microscopic abnormal structures play in the terminal disease are not clear.
However, once these abnormalities spread, causing shrinkage of the brain, certain
memory components suffer. Jongbloed et al. (2013) explained that amyloid plaques
contain a 42-amino acid-long isoform of amyloid β (Aβ42) and that neurofibrillary tangles
consist mainly of hyper-phosphorylated forms of the microtubule-associated protein tau
(TAU). Formations of these abnormal proteins are thought to contribute to the loss or
degeneration of neurons in the brain and the ensuing symptoms of Alzheimer's disease.
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Duara et al. (2013) summarized the importance of amyloid in AD. They
hypothesized that amyloid deposition in the brain may be the earliest detectable
biomarker among subjects destined to develop AD. Brain amyloid levels increase from
6% in 50- to 59-year-old individuals to 50% in those 80-years and older. Elevated brain
amyloid load has been associated with memory decline, increased risk for progression to
mild cognitive impairment (MCI), and dementia among elderly individuals who are nondemented, but not among AD patients in whom amyloid levels have stabilized. Brain
amyloid load is also associated with hippocampal (HP) volume loss and cognitive
impairment among elderly, healthy subjects and patients with MCI. These atrophic
changes, which may be present for many years before clinical symptoms appear or
cognitive decline occurs, represent the neurodegenerative element of AD, and the
possible cause of cognitive impairment and eventual progression to the disease (Duara et
al., 2013). Amyloid plaques are considered an initial event in AD, which is followed by
neurofibrillary tangle formation, neuronal loss and dysfunction, and ultimately dementia.
Hyman et al. (2012) further explained the neuropathology of AD. As mentioned
above, neurofibrillary tangles (NFTs) are intraneuronal fibrils primarily composed of
abnormal tau. NFTs are commonly observed in the limbic regions early on in AD, but
depending on the stage of the disease, NFTs can also be present in other regions of the
brain. Both amyloid plaques and NFTs are widely distributed throughout the neocortex.
However, it must be noted that these two biomarkers of AD do not reflect the complete
molecular pathology of the disease.
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As further research is conducted on AD, more questions continue to be raised.
The Consensus Committee (Hyman et al., 2012), which involved a panel from the United
States and Europe, recommended an “ABC” staging protocol for AD neuropathologic
changes, based on three morphological characteristics of AD: amyloid plaques (A), NFTs
(B), and neuritic plaques (C). The neuritic plaques were most closely associated with
neuronal injury. They were characterized by occurrence of dystrophic neuritis, greater
local synapse loss, and glial activation (Hyman et al., 2012).
Research studies conducted on Alzheimer’s disease have investigated memory
loss/impairment and how it affects patients’ behavior. Castel, Balota, and McCabe (2009)
examined whether aging and AD influenced patient selection of what is important to
recall, attending to information, and later retrieving the information. The pattern
suggested that relative to healthy aging, AD leads to impairments in strategic control at
encoding and value-directed recall, crucial elements of executive control of cognitive
processes. The National Institute of Aging (2009) provided background information for
causes, signs, and symptoms of AD relating to memory loss and thinking skills.
This study examined cognitive/behavioral symptoms of AD patients comparing
those with EOAD to those with LOAD. A more accurate understanding of the
progression of the disease may contribute to efforts at prevention and treatment.
Problem Statement
This study explored collaboration on the part of many scientists, researchers, and
neuropsychologists. There is no known cure for AD (AA, 2013). There are numerous
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research studies that have been conducted on AD patients regarding cognitive functioning
related to a variety of phenomena such as memory impairment (Berwig, Leicht, Hartwig,
& Gertz, 2011; Gagnon & Belleville, 2011; Mathias & Burke, 2009), personality traits
(Duberfstein et al., 2011), emotion perception (Phillips et al., 2010), motivation
(Forstmeier, et al., 2011), and attentional control (Coubard et al., 2011). The fact still
remains that those most significantly affected by AD are individuals ranging from age 65
years to 85 years. This risk factor will most likely affect a significant number of future
baby boomers (AA, 2013). As a result, in January 2011, President Barack Obama passed
the National Alzheimer’s Project Act (NAPA). With the help of the U.S. Department of
Health and Human Services (HHS), this law was created to reduce the prevalence of or
find a cure for Alzheimer’s disease by: (a) coordinating research and services across all
federal agencies regarding AD; (b) speeding up treatment developments that would slow
down, prevent, or overturn the course of the disease; (c) improving coordination of care,
treatment, and early diagnosis of AD; (d) improving outcomes for demographic
populations who are at risk for AD; and (e) forming collaborative efforts globally with
international bodies to fight AD (NAPA, 2011). Therefore, comparing symptoms and
stages of groups with diagnosis of EOAD to that of LOAD may contribute to a greater
increase in our understanding of the progression of the disease. Such an increase in
understanding may contribute to more effective efforts at prevention, diagnosis, and
treatment.

6
Aging changes

The National Institutes of Health (NIH, 2013) explained that as individuals age
the brain and nervous system go through natural changes. The brain and spinal cord lose
nerve cells and weight (atrophy). Nerve cells may begin to pass messages more slowly
than in the past. Waste products can collect in the brain tissue as nerve cells break down,
causing abnormal brain changes such as formation of amyloid plaques and neurofibrillary
tangles. Breakdown of nerves can affect human senses. Reduced or lost reflexes or
sensation can lead to problems with movement and safety.
Cells are the basic building blocks of tissues (Feng & Gao, 2011) and all cells
experience changes with aging (NIH, 2013). They become larger and are less able to
divide and multiply. Many cells begin to function abnormally and progressive loss of
neural cells can occur, especially in the case of AD patients (Feng & Gao, 2011). Waste
products build up in tissues with aging. Therefore, many AD patients loose oxygen and
nutrients in brain cells; as well as the ability to remove carbon dioxide and wastes
(Cheung & Ip, 2011). Mass loss occurs in these tissues, causing them to become lumpy or
more rigid, which results in a process called atrophy (NIH, 2013). Feng and Gao (2011)
suggested cell replacement as an alternative option for fighting neurodegenerative
disorders such as AD.
Because of cell and tissue changes, organs (e.g., the brain) also change as
individuals age. Aging organs slowly lose function. Most people do not notice this loss,
because human organs are not used to their fullest ability (NIH, 2013). Conducting

7
research studies that explored cognitive/behavior symptoms of groups diagnosed with
AD and comparing AD patients diagnosed before age 65 to those diagnosed age 65 and
over, can help better understand the progression of this disease.
This study allowed me to explore the connection of cognitive/behavioral
symptoms of AD to time of onset, which was beneficial. AD patients are considered to be
early onset (EOAD) before the age of 65 and late onset (LOAD) at 65 years and older.
LOAD is the most common type of AD. These factors allowed me to form two research
groups. I compared both cognitive and behavioral symptoms of individuals with EOAD
and LOAD. Then once I conducted statistical analysis, cognitive and behavioral
symptoms scores were determined for each group. As a result of my research, future
treatment, possible prevention, and early intervention/screening can be managed and
shared across all professional disciplines (academic, scientific, private, public,
government, etc.). This, in turn, could lead to more collaboration, which could increase
the probability of finding a cure or at least more effective treatment for AD.

Purpose of the Study
This study explored Alzheimer’s disease (AD), which is the most common form
of dementia (Alzheimer’s Association, 2009), has no known cure, and is fatal to those
who have it. In particular, this study examined whether there is a difference in
progression of the disease based upon early-onset AD (EOAD) or late-onset AD
(LOAD). The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
([DSM-V] APA, 2013), lists Alzheimer’s disease under the category neurocognitive
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disorders (NCDs). The criteria for various NCDs are based on specified cognitive
domains such as complex attention, executive function, learning and memory, language,
perceptual-motor function, and social cognition. Criteria are met for either probable or
possible Alzheimer’s disease with or without behavioral disturbance and severity. By
definition, major or mild NCDs affect functioning, given the central role of cognition in
human life. Thus the criteria for the disorders and the threshold for differentiating mild
from major NCD are based in part on functional assessment. These domains and
descriptors in the DSM-V are slightly different from those included in the DSM-IV. For
the diagnostic criteria for Major or Mild Neurocognitive Disorder due to Alzheimer’s
disease see Appendix A.
Vanderstichele et al. (2012) indicated that accurate clinical diagnostic criteria for
AD are poor because the disease is a complex disorder with overlapping profiles. The
authors posit that depending on the research, clinical diagnoses of AD are correct only
63% to 90% of the time. Clinical diagnosis made at first visit in confirmed cases of AD
results in only 68% of AD cases being straightforward and correct. In remaining cases,
16% of clinical diagnoses made at first visit are incorrect or doubtful. In the early stages
of the disease, diagnostic accuracy is much lower. Vanderstichele et al. (2012) stated that
the development of revised diagnostic criteria that included biomarkers could improve
diagnostic accuracy of AD significantly.
Shoji et al. (2000) and Sunderland et al. (2003) confirmed the relevance of the
neurofibrillary tangles and amyloid plaques associated with AD by using these
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biomarkers for AD present in cerebrospinal fluid (CSF). This research and other studies
revealed that combined use of these markers (Blennow & Hampel, 2003; Engelborghs et
al., 2008; Fagan et al., 2003; Sjogren, Andreasen, & Blennow, 2003) resulted in higher
sensitivity and specificity and met the requirements for discriminating AD from other
specific neurological disorders and normal aging (Vanderstichele et al., 2012).
Vanderstichele et al. (2012) posited that biomarker assessments were helpful in
addressing the AD etiological diagnosis in nonamnestic presentations of AD. In most
cases of posterior cortical atrophy, typical biological AD patterns have low amyloid
deposits with low tau levels, confirming initial reports of underlying AD pathology in
posterior cortical atrophy after autopsy. In addition, low amyloid deposit levels together
with high levels of tau are reliable signatures of an underlying pathology of AD (Braak &
Tredici, 2012; Kawas et al., 2013; Vanderstichele et al., 2012).
It has been more than 100 years since AD was first identified (AA, 2012), but
only within the last 30 years has research by scientists, academics, government programs,
and private and public sectors gained financial-momentum and exposure. Research into
AD symptoms, risk factors, causes, and treatment has uncovered a considerable amount
of information in regards to AD. However, precise physiological changes that trigger AD
development still remain unidentified (AA, 2012).
Over the past 150 years, advances in the treatment of heart disease and cancer are
responsible for postponement of mortality and a marked change in aging
biodemographics. In addition, other improvements in public health and medical care
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during the 20th century have led to considerable increases in life expectancy (Carrillo et
al., 2013). As a result, the principal causes of death have shifted dramatically from
chiefly infectious diseases to cardiovascular disease, cancers, and increasingly,
progressive neurodegenerative dementias such as AD (Kling, Trojanowski, Wolk, Lee, &
Arnold, 2013). If this trend continues, individuals who were born at the beginning of the
21st century can expect to live past the age of 100, nearly double the average life
expectancy only one century ago (Carrillo et al., 2013).
Most individuals with AD usually live 4 to 8 years after their diagnosis (AA,
2012). However, there are those who live as long as 20 years after being diagnosed.
EOAD patients are diagnosed before the age of 65 and LOAD patients are diagnosed on
or after the age of 65. By studying and comparing symptoms of EOAD and LOAD
patients, it may be possible to identify the characteristics that can help increase patient
survivability in general. These individuals live longer in the severe stage of the disease
than any other stage. This slow progression of AD usually means a frightening fate for
AD patients, not to mention having to spend the rest of their years in a nursing home.
Two-thirds of individuals, who die of dementia, usually do so in nursing homes as
compared to 20% of those who die from cancer or 28% of those who die from all other
conditions (AA, 2012). AD is the sixth leading cause of death. In addition, slow
progression of the disease also has a statistical impact on public health (Okie, 2011).
There is an incomplete understanding of the differences in disease progression
between EOAD and LOAD (Panagyres & Chen, 2013; 2014). Disease progression of
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EOAD and LOAD will be examined to determine whether or not cognitive/behavioral
symptoms have a relation to AD time of onset. EOAD is a rare form of Alzheimer’s
disease in which individuals are diagnosed with the disease before age 65 (AA, 2014).
LOAD is the most common form of Alzheimer’s disease, in which individuals are
diagnosed with the disease after age 65 (AA, 2014). There are suggestions that the
underlying pathology may be different when it comes to cognitive and behavioral
symptoms (Eriksson et al., 2014). Eriksson et al. (2014) concluded that there are
differences between EOAD and LOAD in demographics, diagnostic work-up and
pharmacological treatment. The purpose of this study was to investigate
cognitive/behavioral symptoms as related to time of onset, whether that of EOAD and/or
LOAD patients.
Research indicates that memory loss, impairment, and distortion are core features
of Alzheimer’s disease (Sternberg, 2009). Brain structures involved in memory deficits
are also linked to behavior functions (Nadel & Peterson, 2013: Yu et al., 2013). In earlyonset AD, genetic risk factors include amyloid precursor protein (APP), presenilin 1
(PSEN1), and presenilin 2 (PSEN2). In late-onset AD, the apolipoprotein E (ApoE)
protein is also an important genetic risk factor, having at least three variations of its kind
called E2, E3, and E4 alleles. According to previous studies, mutations in these various
genes have been presented on AD timelines according to age (Bagyinszky, Youn, An, &
Kim, 2014). The following research questions and hypotheses guided this study.
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Research Questions and Hypotheses
RQ1: Are there differences in cognitive symptoms between EOAD patients and LOAD
patients?
H01: EOAD patients have the same cognitive symptoms as LOAD patients.
Ha1: EOAD patients have different cognitive symptoms than LOAD patients.
RQ2: Are there differences in behavioral symptoms between EOAD patients and LOAD
patients?
H02: EOAD patients have the same behavioral symptoms as LOAD patients.
Ha2: EOAD patients have different behavioral symptoms than LOAD patients.
Framework
I used the traditional memory model for this research. This model indicated that
memory is the means by which we retain and draw on prior experiences to utilize
information for present experience. Atkinson and Shiffrin (1968) posited that memory
can be perceived in three memory stores: sensory memory, short-term memory, and longterm memory. When AD is present, memory is lost, specifically episodic memory in the
early stage of AD; as the disease progresses, semantic memory is impaired. However,
non-declarative memory is still intact until near death (Sternberg, 2009), which will be
discussed in further detail in Chapter 2.
Further research is needed to understand specific stages of the disease in
comparative groups: EOAD patients versus LOAD patients, as well as behaviors noticed
after cognitive decline. As a result, this study was pursued using quantitative informant
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instruments, the Behavioral Pathology in Alzheimer’s disease (BEHAVE-AD) (Reisberg,
Borenstein, Salob, Ferris, Franssen, & Georgotas, 1987) and the Short Form of the
Informant Questionnaire on Cognitive Decline in the Elderly (Short IQCODE) (Jorm,
1994) as well as a qualitative interview conducted with several of the participating
caregivers on behalf of their AD patients/family members. The research design was a
mixed method approach.
Nature of the Study
I used a mixed methodology in this study, both quantitative and qualitative
approaches. Data was obtained from caregivers of individuals who had been diagnosed
with AD. The caregivers were given a demographic background questionnaire (Bivin,
2013) to complete on behalf of the individual with AD. The BEHAVE-AD Informant
instrument (Reisberg et al., 1987) and the Short IQCODE (Jorm, 1994) were completed
by the caregiver on behalf of the AD patient as well. A qualitative interview was given to
several participants to obtain personal perspectives and to explore symptoms in more
detail. Because the cognitive and behavioral informant instruments, and the demographic
questionnaire, were filled out by the caregiver instead of the actual AD patient,
information was not as precise. The BEHAVE-AD Informant assessed behavioral
symptoms of the AD patient and the Short IQCODE assessed cognitive symptoms. But
before these quantitative tools were presented, I conducted a qualitative interview with
six of the participant caregivers. Once the caregiver completed each assessment, this
information was scored and categorized into EOAD/LOAD. To obtain the present stage
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of the AD patient, a definition for each stage was presented on the demographic
questionnaire, which I handed out to Alzheimer Association Support groups for
caregivers in various locations throughout the state of Texas. Further details were
discussed in Chapter 3.
Information was obtained from experts in the fields of psychology and psychiatry,
as well as from dissertation committee chair and members, to assist in determining
relevant symptoms and stage levels of the AD population. I collected data from the
Alzheimer’s Association, the National Institute of Aging, as well as various partnerships.
In regards to the Alzheimer’s Association, the caregivers were the sole source of
information on behalf of the sample of the AD patient population. The same method was
used to determine the AD stage level; stage levels were defined according to Reisberg’s
seven-stage framework in Alzheimer Association’s website (AA, 2013). Quantitative
analysis drawn from the data (information from the caregiver and symptoms endorsed
from research instruments) provided statistical inferences of the most salient symptoms.
In addition, it was the intent of this study to explore and obtain themes/paradigms that
originated from the qualitative aspect of the research.
Definition of Terms
The following are definitions of cognitive and neurological terms used in
describing Alzheimer’s disease.
Acetylcholine (ACh): a key neurotransmitter that modulates neural processing
within the cortex and between the thalamus and cortex (Savage, 2012).
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Alzheimer’s disease: the major cause of dementia in old age, characterized by
neurofibrillary tangles, amyloid plaques, and neuron loss (Pinel, 2009).
Amyloid: a protein that is normally present in small amounts in the human brain
but is a major constituent of the numerous plaques in the brains of Alzheimer’s patients
(Pinel, 2009).
Apolipoprotein E: a gene product that is a significant risk factor for late onset
Alzheimer’s disease (Bagyinsky et al., 2014).
Atrophy: degeneration or wasting away of an organ, structure, or body part
through disease, inadequate nutrition, or disuse (Colman, 2006).
Cerebrospinal fluid (CSF): colorless fluid produced in the brain that fills the
subarachnoid space that circulates through the cerebral ventricles before flowing
passively into the venous bloodstream (Colman, 2006; Pinel 2009).
Declarative memory: A storage system for declarative knowledge, involving
structures in the “temporal lobes, especially the hippocampus. Information contained in it
is acquired by a form of learning that requires conscious awareness and that occurs
quickly (Coleman, 2006).
Early-onset Alzheimer’s disease (EOAD): a rare form of Alzheimer’s disease in
which individuals are diagnosed with the disease before age 65 (AA, 2014).
Episodic memory: A type of long-term memory for personal experiences and
events (Coleman, 2006).
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Explicit memory: Memory that is revealed when performance on a task requires
conscious recollection of information previously learnt (Coleman, 2006).
Familial AD: early-onset Alzheimer’s disease that runs in families, where copies
of one or two genes are inherited from an individual’s parents (Bagyinsky et al., 2014).
Genetic mutation: a permanent change in the DNA sequence that makes up a
gene. Gene mutations occur in two ways: they can be inherited from a parent or acquired
during a person’s lifetime (NIH, 2014).
Implicit memory: A type of memory that is revealed when learning facilitates
performance on a task that does not require conscious or intentional recollection of what
was learnt (Coleman, 2006).
Late-onset Alzheimer’s disease (LOAD): the most common form of Alzheimer’s
disease in which individuals are diagnosed with the disease after age 65 (AA, 2014).
Mild Cognitive Impairment: a condition characterized by slight amnesia without
dementia or other forms of cognitive impairment, often a precursor of Alzheimer’s
disease (Colman, 2006).
Mutation: a process that creates genetic variation or a change in the “genes or
chromosomes of a cell” (Colman, 2006).
Neurofibrillary tangles: a knotty mass of neurofibrils and insoluble fibers
composed chiefly of breakdown products of the tau protein, occurring in the brains of
most people over 70 years old and found abundantly in the hippocampi and amygdalae of
patients with Alzheimer’s disease and other disorders (Colman, 2006).
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Neurogenesis: the generation of new neurons to replace damaged ones (Colman,
2006).
Neurons: cells of the nervous system that are specialized for receiving and
transmitting electrochemical signals (Pinel, 2009).
Neurotransmitter: a small amine or peptide but also a substance such as the gas
nitric oxide, by which a neuron communicates with another neuron or with a muscle or
gland via a synapse (Colman, 2006).
Non-declarative memory: Memory for non-declarative knowledge, involving
memory systems that do not draw on the individual’s general knowledge (Coleman,
2006).
Precursor: a forerunner, or something that precedes or heralds something else; in
particular, a chemical substance from which another more important substance is derived
or synthesized (Colman, 2006).
Procedural memory: a form of non-declarative memory, which is a storage
system for procedural knowledge, information in it being acquired through a form of
learning that is relatively slow, requiring repetition over many tasks, and often occurring
without conscious awareness (Coleman, 2006).
Semantic memory: A type of long-term memory for factual information about the
world, excluding personal episodes in one’s life (Coleman, 2006).
Sporadic AD: early-onset Alzheimer’s disease without any family history or
inheritance pattern of mutated genes, like that of familial AD (Bagyinsky et al., 2014).
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Significance
The significance of this study is that it contributed to the current knowledge base
regarding AD and illuminated similar/different symptoms and stages related to early
versus late onset of the disease. Many researchers have focused attention on the temporal
lobe of the brain because amyloid plaques and neurofibrillary fibers play important roles
in the spread of AD to brain tissues in this area (Good, Hale, & Staal, 2007).
Khachaturian, Mielke, and Khachaturian (2012) brought attention to cognitive
dysfunction during various stages of AD, and how it influenced patients’ behaviors.
In Chapter 2, I will discuss research that has and is being conducted on memory
and behavioral aspects of AD. There maybe evidence-based knowledge revealed from
studying symptoms and stages of the disease by focusing on the comparison of EOAD to
that of LOAD. This could lead to better and more meaningful ways for caregivers and
clinical professionals to detect/identify symptoms of AD patients at specific stages of the
disease.
Summary
This study was conducted to contribute to the current knowledge base concerning
AD presented by previous researchers. AD is the sixth leading cause of death in the
United States, but is the fifth leading cause of death for individuals aged 65 and older
(AA, 2016). The financial burden to treat AD is approximately $200 to $600 billion
annually. However, when the baby boomer generation reaches the critical age when the
onset of AD appears, the financial cost could increase to $1 trillion, annually (Okie,
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2011). Considering there is no known cure for AD, this study focused on and compared
symptoms and stages of AD in groups who had EOAD versus those who had LOAD. My
intent was to offer a better understanding of the progression of AD. These implications
could in turn be shared with other researchers, scientists, and clinical professionals to
improve future treatment/prevention outcomes. In addition, this research provided
information that could contribute to the development of treatments to address the
continued increase in the aging population’s possibility of inheriting or developing AD.
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Chapter 2: Literature Review
Introduction
Alzheimer’s disease (AD) is the most common form of dementia (Alzheimer’s A, 2009).
Dementia is impairment or loss of memory, especially evident in the learning of new
information, and of thinking, language, judgment, and other cognitive faculties, without
clouding of consciousness (Colman, 2006). AD is a type of dementia or condition that
develops when neurons, or nerve cells, in the brain die. Death of these nerve cells causes
deficits in an individual’s memory, behavior, and ability to think. These impairments
caused by AD can prevent an individual from performing basic bodily functions and
eventually cause death (Pinel, 2009).
The Alzheimer’s Association (AA, 2016) reports that in the United States,
Alzheimer’s disease is the sixth leading cause of death. In Americans over the age of 65
years (LOAD), it is the fifth leading cause of death. It is estimated that 5.4 million
Americans have AD including 200,000 individuals who are considered early onset
sufferers (EOAD), diagnosed before the age of 65 (AA, 2016). Over the next decade, 10
million baby boomers are expected to develop AD. By the year 2050, the prevalence of
AD will increase to between 11 million and 16 million cases across all racial and ethnic
groups (LOAD), specifically those over age 85 (AA, 2012). Other causes of death such as
stroke, heart disease, and prostate cancer, have decreased by 20%, 13%, 8%, respectively,
in the past several years. However, deaths from AD have increased by 66% (AA, 2012).
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In 2012, a total of $200 billion dollars were expended on the care of individuals with AD
and other dementias.
Although AD was identified more than 100 years ago, there is no known cure for
this degenerative disease (AA, 2012). It was only in the past 30 years that widespread
attention has been given to research that involved AD symptoms, risk factors, and
treatment (Cummings, Golde, Sano, & Tariot, 2007; Khachaturian, Khachaturian, &
Thies, 2012). It has only been a few years since collaborations among private,
government, and academic institutions have been formed to create a national research
initiative (NAPA, 2011). Following is an explanation of how this literature review was
accomplished.
Literature Search
The literature search was conducted by retrieving articles from Walden University
library using the PSYCArticles database, peer-reviewed articles retrieved from
subscription copies of Alzheimer’s & Dementia: The Journal of the Alzheimer’s
Association (2012/2013), Archives of General Psychiatry, Clinical Geriatrics: A Clinical
Journal of the American Geriatrics Society, Current Psychiatry, Cognitive Science, and
the Psychological Review. I used the Alzheimer’s Organization website to review
updated information that had been presented by members of Alz.org. I also used several
books to compare information and use during the search process. Words or phrases that I
used to retrieve peer reviewed articles included: Alzheimer’s disease, mild cognitive
impairment, symptoms of Alzheimer’s disease, risk factors for Alzheimer’s disease,
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memory loss, caregivers and Alzheimer’s disease, stages and progression and
Alzheimer’s disease. All sources were evaluated for relevancy of topics concerning
Alzheimer’s disease.
Amyloid Hypothesis and Memory Theory of Alzheimer’s Disease
AD is a syndrome consisting of deficits in memory, reasoning, and judgment, and
changes in behavior, communication abilities, and mood (Berwig, Leicht, Hartwig, &
Gertz, 2011; Gagnon & Belleville, 2011; Mathias & Burke, 2009). Duara et al. (2013)
posited that Alzheimer’s disease occurs as a result of protein accumulation in key areas of
the brain linked to the creation and maintenance of memories and the accuracy of those
memories. Activity in the hippocampus increases in response to this protein accumulation
in an effort to protect these memories. Over time this excess activity can cause damage to
the hippocampus as AD progresses (Gauthier & Molinuevo, 2013).Although there has
been a significant increase in understanding of how the brain changes with AD,
researchers do not know the cause of this fatal disorder.
The amyloid hypothesis is the leading theory explaining AD pathogenesis. Braak
and Del Tredici (2012) posited that aberrant processing of amyloid precursor protein
(APP) leads to the accumulation of insoluble amyloid in the brain. Lelos, Thomas, Kidd,
and Good (2011), Lim et al. (2013), and Nekkiksimmons et al. (2013) published literature
reaching the same conclusion. Neurotoxic amyloid β (Aβ) peptide Aβ42 is an APP
processing product. The gathering or aggregation of Aβ42 into multiple oligomeric forms
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and deposition in amyloid plaques is considered an initial event in AD, which is followed
by neurofibrillary tangle formation, neuronal loss and dysfunction, and then dementia.
Genetic Varieties of Alzheimer’s disease
Neuropathological hallmarks of familial and sporadic AD include extracellular
parenchymal and cerebrovascular amyloid deposits, intracellular neurofibrillary tangles,
and loss of neurons and synaptic integrity in explicit areas of the brain (Kar,
Slowikowski, Westaway, & Howard, 2004; Yu et al., 2013). Genetic and environmental
factors can both contribute to AD development.
Early onset AD (EOAD)/Familial and Sporadic AD
Familial AD runs in families (copies of one or two genes inherited from an
individual’s parents) and sporadic AD or nonfamilial AD has no inheritance pattern of
mutated genes like that of familial AD (Alzheimer’s Association, 2016). EOAD may be
either familial or sporadic and may be caused by mutations in three genes: amyloid
precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2), which are
located on three chromosomes (Bagyinszky, Youn, An, & Kim, 2014). Mutations in the
APP gene will cause an abnormal form of amyloid protein to be produced. Mutations in
the PSEN1 gene will cause an abnormal presenilin 1 protein to be produced. Mutations in
the PSEN2 gene will case an abnormal presenilin 2 protein to be produced (Bagyinsky et
al., 2014).
According to the National Institute of Health, amyloid precursor protein (APP) is
found in the brain and is believed to play a role in neuron formation (NIH, 2014).
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Presenilin proteins help to process amyloid proteins by cutting them into smaller
segments or peptides with the help of other enzymes (Bagyinsky et al., 2014): However
when mutations of the presenilin genes occur, this disrupts the processing of the amyloid
precursor protein, causing overproduction of amyloid-β peptide (Bagyinsky et al., 2014).
This protein fragment can build up in the brain and cause formation of clumps, called
amyloid plaques, with the end result likely leading to neuronal death and to progressive
signs and symptoms of AD (Bagyinsky et al., 2014; Kar et al., 2004).
Point mutations in the gene for amyloid precursor protein (APP) on chromosome
21 have been associated with early-onset (< 65 years) familial AD cases (Yu et al., 2013).
On the other hand, many early onset cases have been linked to alterations in 2 other
genes: PSEN1 on chromosome 14, where most AD risk factor mutations have been
detected; and PSEN2 on chromosome 1. Mutations of these three genes can account for
30%-50% of all autosomal dominant early onset cases (Kar et al., 2004).
Late onset AD (LOAD)/Apolipoprotein E
Bagyinszky et al. (2014) stated that the apolipoprotein E (APOE) gene is inherited
and is an important genetic risk factor for LOAD. Apolipoprotein E is a major cholesterol
carrier in the brain and can be involved in the repair and maintenance of neurons
(Bagyinsky et al., 2014). There are at least three variations of the APOE gene, which
consist of ε2, ε3, and ε4 alleles. The ε4 allele of the APOE gene, on chromosome 19, has
been linked with a significant high risk for late-onset of AD (Bagyinsky et al., 2014;
Brainerd et al., 2013). Kar et al. (2004) explained that having a single copy of the ε4
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allele can increase the chances of inheriting or developing AD 2 to 5 times, but having
two ε4 alleles can raise the chances to more than 5 times. Bagyinsky et al. (2014) report
that ε3 is the most common APOE gene found in the general population. Both ε2 and ε3
may participate in neuronal repair and maintenance. The ε2 allele, on the other hand,
protects against developing AD (Bagyinsky et al., 2014; Kar et al., 2004). Both ε2 and ε4
alleles have been associated with chromosome 19. Nonetheless, Kar et al. (2004)
determined that none of the AD cases in their sample were associated with any of these
genes.
Recent postmortem research (Yu et al., 2013) was conducted on participants
(N=581) who came from two longitudinal clinical-pathological studies, the Religious
Orders Study (ROS) and the Memory and Aging Project (MAP). The authors’ goal was
to test the hypothesis of an association of APOE ε4 allele with cognitive decline.
Participants underwent cognitive performance evaluations annually for 18 years prior to
death. Assessments provided objective evidence suggesting that ε4 is an important
determinant of late-life change in cognition (including terminal decline) and may
contribute to AD pathology (Yu et al., 2013). There still remains controversy concerning
whether ε4 is a risk factor in the transition from mild cognitive impairment to AD
(Brainerd et al., 2013).
Neurofibrillary tangles are abundant in the brains of individuals with AD,
especially in the entorhinal cortex, hippocampus, amygdala, association cortices of the
frontal, temporal, and parietal lobes, and certain subcortical regions projecting to these
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regions (Kar, Slowikowski, Westaway, & Howard, 2004). Neurofibrillary tangles are
composed of paired helical filaments (PHF) and sometimes single straight filaments
containing an abnormal hyperphosphorylated form of the microtubule-associated protein
tau. PHF formation reduces the ability of tau to stabilize microtubules which leads to
neuronal transport disruption and eventually to the death of affected neurons. The degree
of neurofibrillary pathology, and specifically the amount of cortical neurofibrillary
tangles, positively correlates with the severity of dementia (Kar et al., 2004).
Yu et al. (2013) stated that neuritic plaques are multicellular lesions containing
amyloid peptide deposits surrounded by dystrophic neuritis, reactive astrocytes, and
activated microglia. The main amyloid peptides found in the plaques are β-amyloid1-42
(Aβ1-42) and Aβ1-40p peptides that are generated by proteolytic cleavage of APP. Aβ1-42 is
deposited first and is the predominant form in senile plaques, but Aβ1-40 is deposited later
on during progression of AD. Evidence suggests that Aβ peptide accumulation in the
brain, over time, initiates or contributes to AD pathogenesis (Kar et al., 2004; Yu et al.,
2013). Overproduction or reduced clearance, or both, of Aβ peptides are likely key to
amyloid aggregation. This in turn adds to neurofibrillary tangle development and
subsequent neuronal degeneration. Research studies of adult animals and of APP
transgenic mice demonstrate that injection of aggregated Aβ induces neuronal loss in
selected regions of the brain (Kar et al., 2004; Yu et al., 2013).
Vloeberghs, Van Dam, Coen, Staufenbiel, and De Deyn (2006) conducted in vivo
research involving APP23 transgenic mouse models, which are valuable animal models
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of AD. These researchers suggested that transgenic mice models mimic memory deficits
as well as several devastating behavioral disturbances of demented patients. These
transgenic mouse models approximate the clinical situation and are able to provide an
instrument to evaluate diverse therapeutic interventions (Vloeberghs et al., 2006). Aβ
injection peptide can increase formation of neurofibrillary tangles in tau transgenic mice
(Vloeberghs et al., 2006). Evidence of this relation was initially observed in family
members with familial AD. Although results suggest that Aβ peptides play a role in the
neurodegenerative process, both the role they play in the brain and the means by which
they cause neuronal loss and tau abnormalities in AD are poorly understood (Kar,
Slowikowski, Westaway, & Howard, 2004).
Who is affected by Alzheimer’s disease?
Individuals affected by AD experience a variety of symptoms that can ultimately
lead to death. The healthcare system, the government, academia, and scientific
communities, as well as family members and caregivers are also affected by the effects of
this degenerative disorder (Delavande, Hurd, Martovell, & Langa, 2013; Reuben, 2007;
Stefanacci, 2008). The baby boomers will comprise about 10 million individuals who
will contract the disease over the next decade. With this in mind, the healthcare system as
well as the government will need to understand and prepare for the impact this will have
on future spending, medical and psychological treatment, outcomes, and prevention
measures (Furiak et al., 2012; Mielke et al., 2012; Naylor et al., 2012; Wimo, Jonson,
Bond, Prince, & Winblad, 2013). In 2012, the estimated cost of treatment for Alzheimer’s
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patients was $200 billion (Okie, 2011). There are also roughly 10 million unpaid
caregivers who are currently assisting individuals who have been diagnosed with the
disease.
Brain Functions and Structures
Postmortem studies on AD have focused on some of the brain structures involved
in memory, such as the hippocampus (Nadel & Peterson, 2013; Yu et al., 2013).
Examinations of AD patients have also identified some of the microscopic aberrations
associated with the disease process (unique tangled fibers and plaques in the brain tissue).
Even though lesion techniques provide a basic foundation for understanding the brain’s
relationship to behavior, these techniques are limited because they cannot be performed
on the living human brain (Kar, Slowikowski, Westaway, & Howard, 2004).
If scientists want to understand physiological processes and functions of the brain,
they have to use in vivo research, which is performed solely on animals (Vloebergs, Van
Dam, Coen, Staufenbiel, & De Deyn, 2006). Early in vivo research consisted of inserting
microelectrodes into the brain of an animal (i.e., a cat, mouse, or a monkey) in order to
obtain a single-cell recording of a single neuron in the brain. In humans, Langeslag and
van Strien (2009) revealed how the brain is being studied by using electrical analyses
(e.g., electroencephalograms and event-related potentials), X-ray techniques (e.g.,
angiograms and computer tomograms) and magnetic field computer analyses within the
brain (magnetic resonance imaging). Taylor, Rastle, and Davis (2013) conducted a
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similar study showing blood flow and metabolism computer analysis within the brain
(positron emission tomography and functional magnetic resonance imaging).
Yerokhim et al. (2012) conducted a pilot study demonstrating the benefits of
exercise on memory and cognition using EEG and ERP. Currently, none of these
techniques provides definite mappings of exact functions to particular brain structures,
regions, or processes (Baxter & Bucci, 2013; Brainerd et al., 2013; Yu et al., 2013).
However, some discrete brain structures, regions, or processes have been found to be
involved in particular cognitive functions (Nadel & Peterson, 2013). Thus, present
understanding of this involvement allows only correlational evidence of some type of
relationship. Sophisticated analyses can highlight increasingly precise relationships, but
research is not at the point where a specific cause-effect relationship between a given
brain structure or process and a particular cognitive function can be determined. Lastly,
the above techniques provide the best information only in combination with other
experimental techniques for understanding cognitive functioning complexities (Baxter &
Bucci, 2013; Brainerd et al., 2013; Yu et al., 2013).
Brain Regions
The brain is part of the nervous system and can be viewed as being divided into
three major regions: forebrain, midbrain, and hindbrain (Sternberg, 2009). The forebrain
is the region located toward the top and front of the brain and contains the cerebral
cortex, the basal ganglia, the limbic system, the thalamus, and the hypothalamus. The
limbic system is important to emotion, motivation, memory, and learning. Therefore, the
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limbic system is important to Alzheimer’s disease, especially if memory is distorted or
impaired. MacDuffie et al. (2012) posited that memory distortion in AD is a clinically
relevant concern. AD patients and their caregivers frequently report incidents of getting
lost, misplacing possessions, and confusing present experiences with past ones. The
limbic system allows individuals to better adapt to a changing environment. It comprises
three central interconnected cerebral structures, which includes the amygdale, the septum,
and the hippocampus (Sternberg, 2009).
Wolk and Dickerson (2011) indicated that the medial temporal lobes (MTL),
particularly the hippocampus, play a central role in episodic memory function. The most
profound forms of amnesia are associated with damage to these brain structures.
Alzheimer’s disease is the most common form of acquired amnesia (Wolf & Dickerson,
2011). Given the involvement of neuropathology, specifically neurofibrillary tangles in
the medial temporal lobes (MTL) of AD patients, much of the work examining AD
memory impairment has focused attention on the hippocampus and other structures of the
MTL (Wolk & Dickerson, 2011).
The hippocampus is a structure within the limbic system (Nadel & Peterson,
2013). The hippocampus and nearby cerebral structures are important for explicit
memory of experiences and other declarative information. The hippocampus also plays a
key role in declarative information encoding. According to Nadel and Peterson (2013), it
is involved in the transfer of newly synthesized information into long-term structures
supporting declarative knowledge. The basal ganglia are memory structures responsible
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for nondeclarative memory forms. These structures are primary in controlling procedural
knowledge, one form of nondeclarative memory (Willems, Salmon, & Van der Linden,
2008).
Memory Processes
Memory loss, memory impairment, and memory distortion, as well as impairment
in thinking, are core features of AD (MacDuffie et al., 2013). Therefore, a general review
of memory processes can be useful in understanding these specific memory symptoms in
AD.
Memory is the means by which individuals retain and draw on prior experiences
in order to function in the present. It is the ability of the brain to store and access learned
experiences (Sternberg, 2009). Memory and learning are two ways of thinking about the
same thing. Each of these processes deals with the brain’s ability to change in response to
experience. Memory allows changes of the brain to be stored and then reactivated (Pinel,
2009).
MacDuffie et al. (2013) conducted a study on memory distortions comparing
performance of mild-to-moderate AD patients to that of aged-matched, healthy older
adult participants on short-term memory (STM) and long-term memory (LTM) tasks.
Participants were tested on the STM version of the Deese-Roediger-McDermott (DRM)
task to measure recall memory for four-word lists and were tested on the LTM version of
the DRM task to measure recall memory for 12-word lists. AD participants showed
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greater impairment on the LTM task than the STM task. Authors concluded that STM
impairment with some preserved semantic process is evident in AD.
Memory is the capacity for storing and retrieving information. Encoding, storage,
and retrieval are the three processes involved in memory. These three processes
contribute to whether information is remembered or forgotten (Sternberg, 2009).
Encoding
Vermeulin, Chang, Mermillow, Pleyers, and Corneille (2013) agreed that
processing information into memory is called encoding. There are several ways of
encoding information verbally. Structural encoding entails focusing on what words look
like; phonemic encoding entails focusing on the sound of words; and semantic encoding
entails focusing on the meaning of words. Castle, Balota, and McCabe (2009) focused on
encoding, implying that older adults perform poorer on tasks involving executive
processes, working memory and frontal lobe functions, leading to difficulties on tasks
such as attention and memory. Hence, examination of attention control impairments and
behavioral development measures can serve as useful early diagnostic measures of AD.
Storage
After information enters the brain it is stored. Atkinson and Shiffrin (1968)
proposed the three-stage model used to describe the storage process. This model
indicated that information is stored in three memory systems (sensory memory, shortterm memory, and long-term memory) sequentially.
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Sensory memory. Winkler and Cowan (2005) explained that sensory memory
stores information which is received through sense organs, but only for an instant. The
information is unprocessed, but sensory memory capacity is very large. Information is
sometimes transferred from sensory memory into short-term memory (STM), which
holds information for about 20 seconds. However if this information is rehearsed it can
stay within STM between 15 and 30 seconds. Rehearsal of information in STM can be
accomplished by repeating items verbally (Winker & Cowan, 2005).
Short-term memory/working memory. Vermeulen, Chang, Mermillod, Pleyers,
and Corneille (2013) and other researchers referred to short-term memory as working
memory. Instead of referring to it as a temporary information storage system, working
memory is an active system used to manipulate information. It holds information
individuals are consciously thinking about in the present, i.e., processes like adding and
subtracting, problem solving, thinking about the meaning of what is heard or read, or
carrying out a sequence of operations. Working memory holds information that is derived
from sensory inputs or retrieved from long-term memory (Vermeulen et al., 2013).
The concept of working memory was first introduced by Baddeley and Hitch
(1974). The authors proposed that short-term memory be reformulated as a working
memory that could perform a number of different functions. Baddeley and Hitch (1974)
believed that Atkinson’s and Shiffrin’s (1968) short-term memory described in the multistore model was too simple. The model depicted STM as a single system or store without
any subsystems. Baddeley and Hitch (1974) indicated that working memory is short-term
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memory, but instead of information going into one single system, there exist different
systems for different types of information. The authors suggested that working memory
consists of a central executive that controls and coordinates operation of the phonological
loop and the visuo-spatial sketch pad, which are two subsystems. The central executive
directs the memory system and allocates data and resources to the two subsystems. The
visuo-spatial sketchpad is used for navigation and stores and processes information in a
visual or spatial form. The phonological loop is responsible for manipulation of speechbased information and deals with written and spoken material.
Long-term memory. Winkler and Cowan (2005) indicated that information can
be transferred from short-term/working memory to long-term memory (LTM) and vice
versa. LTM may store information for a lifetime and it may have an infinite amount of
capacity. However, because information stays in an individual’s LTM does not mean that
the information will be readily or easily retrieved (Winkler & Cowan, 2005). Retrieval is
the process of getting information out of long-term memory and into short-term or
working memory. The brain organizes information by category in LTM. Another way
information is organized in LTM is by connection to other information, relevance, and
familiarity. Tulving (1972) proposed subdivisions of long-term memory, e.g., explicit
memory, which involves episodic and semantic memory, and implicit memory which
involves procedural memory.
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Explicit and Implicit Memory
Learning changes the brain and memory refers to the storage and retrieval of
information of these changes (Pinel, 2009). Memory includes both explicit and implicit
memory, which are two functionally and anatomically separable long-term memory
systems in humans (Pinel, 2009). Long-term memory stores a lifetime of information
and allows the retention of physical skills and word meanings that have been learned.
Experts and research psychologists that gain insight into memory from amnesia victims
are able to distinguish between explicit and implicit memories (Eakin & Smith, 2012;
Tulving & Schacter, 1990; Willems, Salmon, & Van der Linden, 2008). As a result,
amnesia patients have been studied to gain valuable insight into memory functioning in
general.
Explicit Memory: Episodic and Semantic
Gold and Budson (2008) posited that explicit memory, also referred to as
declarative memory, is the intentional memory or conscious recollections of facts and
events gained from past experiences (e.g., cooking, driving to work, and using the
computer). Explicit memory is also referred to as declarative memory because it can be
remembered and described in words (Tulving & Schacter, 1990). Older individuals often
experience problems with explicit memory (Ward, Berry, & Shanks, 2013).
Lah and Smith (2014) reported differential relations between two varieties of
explicit long-term memories: episodic and semantic memories. These authors conclude
that children with semantic memory impairments who experience medial temporal lobe
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epilepsy have problems with reading comprehension, spelling, and reading accuracy.
However, children with episodic memory impairments do not experience any problems in
reading comprehension, but do have disturbance in spelling and reading accuracy (Lah &
Smith, 2014). As in AD, these children do not have the ability to store new information,
which would be the case of spelling and reading accuracy that involves new meaning of
words and being able to spell new words. Glosser, Friedmand, and Grugan (1999)
conducted a study on 21 AD patients and 27 matched controls to understand why AD
patients performed slightly below controls on all reading and spelling tasks. The authors
concluded that the mild alexia and agraphia in AD reflected semantic deficits and
nonlinguistic impairments, which occur in patients with focal lesions in the left
hemisphere.
In other words, Glosser et al. (1999) explained that:
“basic orthographic and phonological knowledge that relies on procedural
integrity mediated by the regions within the left, language-dominant
cerebral hemisphere remain intact through the middle stages of AD. However,
lexical-semantic, episodic, and working memory functions that are subserved by a
more distributed cerebral network become impaired in the early stages of AD.
This can result in oral and written language disturbance seen in individuals with
probable AD,” p. 357.
Episodic memory. Gold and Budson (2008) suggested that there are six cognitive
domains that are commonly disturbed in individuals suffering from AD. They include
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memory, language, executive functioning, visuospatial functioning, affect, and attention.
Memory impairment is the central problem of all the disturbances. Memory problems are
also one of the main reasons for admission to residential nursing facilities. A longitudinal
study reported that annual savings of $4 billion could be achieved by delaying the onset
of nursing home care by 1 month for elderly adults with dementia illnesses (Gold &
Budson, 2008). Knowledge of the specific memorial processes that are impaired in AD
may be important to researchers and scientists developing therapies and assessing the
efficacy of those therapies. Gold and Budson (2008) characterized AD as a progressive
neurodegenerative disease manifested by cognitive disturbances, the earliest and most
prominent being impaired episodic memory.
Episodic memory is a form of explicit memory that is most affected by amnesia
(Pinel, 2009; Wolk & Dickerson, 2011).Episodic memory is a part of long-term memory,
which involves conscious thought and is declarative. Episodic memory also involves
storing information about events or episodes that have occurred throughout an
individual’s life (McLeod, 2010).
A number of episodic memory measures involving verbal list learning tasks have
been used to diagnose and monitor disease progression in AD (Wolk & Dickerson, 2011).
Immediate recall, delayed free recall, and recognition memory are memory measures
often assessed using verbal list learning tasks. However, there is a major debate in
memory literature of whether recollection is differently represented in the MTL relative
to familiarity (Wolk & Dickerson, 2011). Serra et al. (2010) explained that recollection
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and familiarity are two types of processes involved in episodic memory recognition.
Serra et al. (2010) stated that “recollection is the conscious re-experience of a previous
event, and familiarity is the feeling of having previously encountered a stimulus with no
associated contextual information,” p. 316.
Individuals with amnesic mild cognitive impairment (a-MCI) had an increased
risk of developing Alzheimer’s disease (Serra et al., 2010). Previous studies have
established characteristic episodic memory impairment in a-MCI, with early recognition
dysfunction. Serra et al. (2010) conducted a study on 19 patients who had been diagnosed
with a-MCI and compared them with 23 healthy patients who were matched for sex, age,
and education The authors used the process dissociation procedure (PDP) and the
remember/know (R/K) procedure to assess whether the patient group recognition deficits
were due to recollection selective impairment rather than familiarity. Both procedural
results revealed selective preservation of familiarity in a-MCI patients. During the study
phase of the R/K procedure, MCI-patients showed significant recollection impairment for
words that were anagrammed or read. Serra et al. (2010) hypothesized recollection and
familiarity as being independent processes coupled with different anatomical substrates.
Semantic memory. Semantic memory is also a form of explicit memory and it is
an accumulation of factual knowledge, but it is not usually affected by amnesia.
However, semantic memory is affected by AD (Pinel, 2009; Wolk & Dickerson, 2011).
Perri, Zannino, Caltagirone, and Carlesino (2012) further discussed distinctions of longterm memory. Semantic memory is another part of long-term memory that also involves
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conscious thought and is declarative. This part of long-term memory includes knowledge
about word meaning as well as general knowledge. Semantic memory is also responsible
for storing information about the world. In a disease stage of AD, the authors explain that
patients may not be able to name objects or describe the semantic characteristics of
concepts. However, they may still possess the ability to produce superordinate category
names of objects or place them in the correct semantic category (Perri et al., 2012).
Implicit Memory: Procedural Memory
Implicit memory, referred to as nondeclarative memory, is the unintentional
memory or unconscious recollections of facts and events gained from past experiences
(Tulving & Schacter, 1990). Generally, implicit memory is not affected by age (Ward,
Berry, & Shanks, 2013). Facets of implicit memory appear to remain intact in AD victims
through final disease stages until death.
Procedural memory. Procedural memory is a form of implicit memory (longterm memory), which involves knowing how to do things such as memory of motor
skills; it is not generally affected by AD (Tulving & Schacter, 1990). This nondeclarative
act, procedural memory, does not involve consciousness, and it is an automatic response.
Knowing how to ride a bike is an example of procedural memory (Willems, Salmon, &
Van der Linden, 2008). Distinction between procedural and declarative memory came
from research on patients with amnesia (Gobel et al., 2013). Procedural memory and
emotional responses are two forms of nondeclarative memory. Procedural memory,
associated with some forms of semantic memory, is not affected by amnesia or damage to
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the hippocampus (Willems et al., 2008). However, it is affected by damage to the
cerebellum or disorders that alter the basal ganglia (Gobel et al., 2013). The cerebellum is
most connected to working memory and its adaptive models of working memory
processing are fed back to the frontal lobe for control processes. It allows for the mental
manipulation of information during memory encoding (Gobel et al., 2013). Emotional
responses are intense personal memories that have close association with the amygdala,
which manages fear reactions. Both the amygdala and the hippocampus have close
association with each other and each plays key roles in traumatic experiences that
provoke anxiety (Willems et al., 2008).
Implicit habit learning is not linked to higher level cortical association because
AD patients perform normally on implicit habit learning tests, confirming that habit
learning does not rely on explicit memory and the MTL brain regions that subserve
explicit memory (Eakin & Smith, 2012). This information supported other studies (Gobel
et al., 2013; Wilkinson et al., 2011) confirming that the basal ganglia played a key role in
implicit habit learning of AD patients. However, there are other researchers who
disagreed and believed that working memory mechanisms were the reasons AD patients
performed normally on implicit habit learning tests (Nosofsky et al., 2012; Smith, 2008).
Implicit skill learning depends on nondeclarative memory that operates
independent of the MTL memory system and, instead, depends on corticostriatal circuits
between the basal ganglia and cortical areas supporting motor function and planning
(Gobel et al., 2013). Basal ganglia are a collection of nuclei deep to the white matter of
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cerebral cortex, which are inhibitory. The function of the basal ganglia is complex and
contributes to some of the subconscious aspects of voluntary movement such as
inhibiting tremor and accessory movements (Wilkinson, Khan, & Jahanshahi, 2009).
The basal ganglia do not initiate movement, but contribute to complex motor
circuit coordination (Wilkinson et al., 2009). This region of the brain is associated with
four neurotransmitters: acetylcholine, dopamine, gamma-aminobutyric acid (GABA), and
serotonin (Pinel, 2009). Acetylcholine levels are greatly reduced in AD patients. The
reduction in acetylcholine is the result of degeneration of the basal forebrain, which is a
midline area located above the hypothalamus (Pinel, 2009). Neurotransmitters and
modulators such as acetylcholine (ACh), serotonin, noradrenaline and somatostatin were
altered in patients with AD. Karr, Slowikowski, Westaway and Mount (2004) indicated
that the amount of activity of the ACh-synthesizing enzyme, choline acetyl-transferase
(ChAT) in the neocortex was significantly decreased, correlating positively with the
severity of dementia. Decreased choline uptake, and ACh release and cholinergic
neuronal loss from the region of the basal forebrain further indicated a selective
presynaptic cholinergic deficit in the hippocampus and neocortex of the brains of
individuals with AD.
Acetylcholine also appeared to enhance neural transmission associated with
memory (Hartig et al., 2014; Kar et al., 2004). High concentrations of acetylcholine were
found in the hippocampus of normal people and low concentrations of this
neurotransmitter were found in individuals with Alzheimer’s disease. Moreover, AD
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patients showed severe loss of brain tissue that secreted acetylcholine. Croxson et al.
(2012) explained that acetylcholine had been implicated in episodic memory, which was
damaged in AD. Acetylcholinesterase inhibitors (AChEIs) such as donepezil,
galantamine, and rivastigmine work by raising ACh levels and has demonstrated
significant symptomatic efficacy in AD (Parsons et al., 2013).
The three AChEI’s underlying mechanisms were distinguished by target protein
specificity (Parsons et al., 2013). Donepezil independently has interacted with neuronal
nicotinic Ach receptors and is a specific reversible inhibitor of AChE. Rivastigmine, in
contrast, is a pseudo-irreversible AChE inhibitor. Rivastigmine has a similar affinity level
for butyrylcholinesterase (BuChE), which is a non-specific enzyme that hydrolyses ACh
and other cholinesters, which are predominantly outside the CNS, with brain levels that
have increased to severe AD. Galantamine has a potential link to amyloid-beta clearance.
This AChEI is a selective, reversible inhibitor, which enhances intrinsic ACh action on
nicotinic receptors (Parsons et al., 2013). AChEIs have proven to slow cognitive decline,
although there is lack of memory improvement. Croxson et al. (2012) suggested that this
was due to acetylcholine having a possible role in boosting attentional performance or
cortical function.
Symptoms and Stages of Alzheimer’s Disease
AD is characterized by the onset of impairments in memory and executive
function, in addition to cognitive and behavioral problems, such as depression, apathy,
and agitation (Wilson, Arnold, Beck, Bienias, & Bennett, 2008). AD patients have been
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known to have different symptoms at different stages of the disease. It is also hard to
place individuals in any one stage of AD because the stages can sometimes overlap (AA,
2013).
Dr. Barry Reisberg at the New York University School of Medicine’s Sillberstein
Aging and Dementia Research Center developed a seven-stage framework for AD (see
Appendix B). He indicated that not everyone who develops the disease will have the
exact symptoms, or the same rate of progression (AA, 2013).
Risk Factors for Alzheimer’s disease
Age and sex are consistent risk factors for Alzheimer’s disease (Kalaria et al.,
2008; Perez et al., 2012). Most individuals who have been diagnosed with AD are 65years-plus (LOAD) and are women. They often experience low literacy, which is linked
to poverty or lower socioeconomic status, leading to poor health, and lower access to
healthcare. According to prevalence studies such as the Chicago Health and Aging
Project (CHAP) and the Aging Demographics and Memory Study (ADAMS)
approximately two-thirds of Americans with AD are women. Of the 5.2 million older
than 65 years with AD in America, 3.4 million are women and 1.8 million are men. The
ADAMS study revealed that 16% of females over 71 years of age have AD compared to
11% of males (AA, 2013).
Other risk factors include genetic association and risk genes--many times family
members of the diagnosed AD patient have more likelihood of inheriting a predisposition
or vulnerability to the disease as well. The gene Apolipoprotein E (APOE ε4 allele) and
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the gene SORL1 are also risk factors for AD and they are usually linked to older women
who have been diagnosed with LOAD (Brainerd, Reyna, Petersen, Smith, & Taub, 2011).
For example, the gene APOE ε4 allele is apparently linked to specific decreases in AD
patients’ functional connectivity, according to EEG coherence studies. Other risk factors
that are associated with AD include stroke injuries, vascular diseases, type 2 diabetes,
obesity, hypertension, and decreased physical activity (Bassil & Grossberg, 2010; Mathis
& Burke, 2009; Solfrizzi, et al., 2013).
Diagnosis of Alzheimer’s Disease
Handen et al. (2012) agreed with research that a definitive diagnosis of AD cannot
be made until the death of an individual. It depends on the identification of amyloid
plaques and neurofibrillary tangles at brain autopsy. Deposition of amyloid usually
begins about 10 years prior to clinical symptoms (Handen et al., 2012). This finding is
usually accomplished with the help of brain imaging, e.g., positron emission tomography
(PET). Brain damage associated with AD also includes many regions of the brain that
perform significant memory functions such as the medial temporal lobe and the prefrontal
cortex.
The Alzheimer’s Association Report (AA, 2013) indicated that a diagnosis of AD
is usually made by a primary care physician (PCP). This individual often obtains medical
and family history comprising psychiatric history and cognitive and behavioral changes.
The PCP will also ask family members or caregivers about the AD patient to gain input.
Additionally, the PCP will conduct cognitive, physical, and neurological examinations,
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and will often have the patient undergo MRI to help identify brain changes (Mathis &
Burke, 2009). The MRI helps to detect such brain changes as strokes or tumors that can
explain the individual’s symptoms. In 2011, new criteria and guidelines were proposed
by the NIA and the Alzheimer’s Association for the diagnosis of AD, which are updated
diagnostic criteria and guidelines proposed in 1984 by the Alzheimer’s Association and
the National Institute of Neurological Disorders and Stroke (AA, 2013; NIA, 2013).
Thomas and Fenech (2007) conducted a review on genome mutation and AD,
which is similar to memory profiling; this is helpful in identifying MCI cases that will
eventually progress into AD. These authors proposed that AD patients could be clinically
diagnosed with an approximate accuracy between 60 and 70%, based on cognitive
impairment and behavioral change criteria. The criteria were based on the National
Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease
and related Disorders Association (NINCDS-AD & DA), which are still measured by the
mini-mental state examination (MMSE). This examination allows a quantitative measure
of cognition status to be conducted (AA, 2013; Almkvist & Tallberg, 2009).
Screening for Alzheimer’s disease
The Centers for Medicare and Medicaid Service (CMS) recommended assessment
tools for the detection of cognitive impairment (Cordell et al., 2013; Dowling, Herman,
La Rue, & Sager, 2010; Kawas et al., 2013). The Alzheimer’s Association convened to
develop an expert group (Alzheimer’s Association Medicare Annual Wellness Visit
Algorithm for Assessment of Cognition) that would provide recommendations to primary
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care physicians in the screening and detection of dementia to reduce the prevalence of
delayed or missed diagnosis. The patient or informant to be screened would be observed
by the primary care physician. The PCP would then review Health Risk Assessment
information, conduct unstructured queries during the annual wellness visit (AWV), and
utilize structured cognitive assessment tools. This recommendation was due in part to a
number of studies supporting the fact that 27%-81% of patients in primary care who are
affected with cognitive impairment go unrecognized/undiagnosed (Cordell et al., 2013).
Although there is growing attention among developed nations concerning
medical, emotional, social, and financial burdens of Alzheimer’s disease, there is no
definite answer of whether or not screening is beneficial compared to its costs (Furiak,
2012). Nonetheless, most agree that if screening is done early on with patients who have
the potential or high risk of developing dementia/AD, both patients and caregivers can
initiate planning, organize ongoing care, prepare for long-term planning for both social
and financial well-being, prepare to have care-giving training, plan for stress
management, or rule out dementia early on in order to search for alternative symptom
causes. As a result, treatment can begin much sooner, whether it is pharmacological or
non-pharmacological (Borson et al., 2013; Furiak et al., 2012).
Treatment/Prolongation of Alzheimer’s disease
Non-pharmacological Therapy
Treatment of AD consists of both non-pharmacological and pharmacological
therapy models. The non-pharmacological therapy model is usually conducted by trained
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professionals (i.e., psychiatrists, psychologists, or master-level clinicians), who follow
practice guidelines recommended by the APA, which put emphasis on neuropsychiatric,
psychiatric, and behavioral symptoms. Logsdon, McCurry, and Teri (2007) focused on
using evidence-based psychological treatments (EBTs) for dementia patients with
behavioral disturbances. Kazdin (2011) suggested that EBTs are the interventions
carefully evaluated in research. Evidence-based practice is a broader term. It refers to the
clinical practice that is informed by evidence about interventions, clinical experience, and
patient needs, values, and preferences and their integration to make decisions about
individual care.
The American Psychological Association (APA) Task force set criteria for EBTs
for psychological disorders, which have specific coding criteria (APA, 2007). The criteria
specified that studies have to treat the same symptom, target problem, or diagnosis.
Logsdon et al. (2007) used predetermined behavioral disturbance levels as an eligibility
requirement. Treatment interventions involved the progressively lowered stress threshold
(PLST) theoretical framework for outcomes between treatment and control groups. The
protocol was based on a behavioral problem solving theoretical framework.
Logsdon et al. (2007) discussed three studies, which are collectively known as
The Seattle Protocol. The first study included patients who were diagnosed with dementia
and depression. The goal of the intervention was to decrease depressive behaviors and
increase pleasant events. In the second study, the intervention was combined with a
home-based program to decrease behavioral disturbances and improve participants’
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physical function. For the third study, the intervention goal was to improve patient
caregivers’ well-being and decrease behavioral disturbances (Logsdon et al., 2007).
Logsdon et al. (2007) pointed out that results using the PLST indicate that all
psychological interventions appear most effective when behavioral problem solving is
provided by or supervised directly by clinical professionals who have expertise in both
behavior therapy and dementia care. Next, psychological interventions that meet EBT
criteria work most effectively with patients with anxious or depressive behaviors. More
research is required to prove EBT’s efficacy with patients who are severely agitated.
Lastly, behavioral disturbances appear less often in early stage dementia patients than
they do in patients at the late stage or progression of the disease.
Logsdon et al. (2007) also noted that the progressive worsening of cognitive
impairment in individuals with dementia has proven to be a challenge when applying
EBT criteria to interventions for behavioral disturbances. Continual adjustment of
treatment plans, expectations, and approaches is required depending on the patient and
the patient’s support system, including the caregiver. Proven efficacy and investigation of
treatment approaches, such as cognitive behavior therapy, life review, and
psychodynamic therapy, commonly used with older adults have not been conducted on
dementia patients who experience behavioral disturbances (Logsdon et al., 2007).
Pharmacological Therapy
Drug delivery to the central nervous system (CNS) is a challenging
pharmacological therapy in treating Alzheimer’s disease. According to Khawli and
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Prabhu (2013), the blood-brain barrier (BBB) only allows molecules that have low
molecular weight to enter the brain via the bloodstream through the transcellular route.
Khawli and Prabhu (2013) indicated that “less than 10% of therapeutic agents for
neurological disease enter into clinical trials because of poor brain penetration,” p. 1471.
Research efforts focused on manipulating drug characteristics or using endogenous
transporters or receptors at the BBB. This can only be accomplished through better
understanding of the CNS and the physiology and pathophysiology of the CNS (Khawli
& Prabhu, 2013).
The Alzheimer’s disease Assessment Scale-cognitive subscale (ADAS-cog) is an
instrument used to measure cognition in clinical trials. The Food and Drug
Administration (FDA) proposed the use of quantitative disease-drug-trial models such as
the ADAS-cog in order to improve drug research and product development for
individuals with AD (Gomeni et al., 2012). The authors posit that it is better to test
modifying drugs at the earliest stage of AD as well as treat symptoms early on to
maintain functional capacity of patients.
Acetylcholine (ACh) is a small-molecular neurotransmitter, which is created by
adding an acetyl group to a choline molecule (Baxter & Bucci, 2013). Acetylcholine
transmits different kinds of messages to different parts of the brain (adjacent cells), which
are brief and rapid (Pinel, 2009). Enzymes are used to break apart neurotransmitters.
Baxter and Bucci (2013) indicated that the enzyme acetylcholinesterase is used to break
down the neurotransmitter acetylcholine. Cholinergic precursors are chemicals used to
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produce acetylcholine in neurons. Neurons releasing acetylcholine are said to be
cholinergic (Pinel, 2009).
Schatzberg, Cole, and DeBattista (2010) informed that the first drug FDAapproved to treat AD was tetrahydroaminoacridine (THA; tacrine). This drug was used in
Australia to reverse drug-induced coma. Tacrine is a central cholinesterase inhibitor that
was thought to act by raising brain levels of acetylcholine and increasing cholinergic
brain activity. As a result, it was used to treat AD patients who had mild to moderate
dementia (Schatzberg, Cole, & DeBattista, 2010). It is rarely used today because it is
hepatotoxic, which is damaging or destructive to liver cells.
Today, the cholinesterase inhibitors (ChEIs) donepezil, galantamine, and
rivastigmine are used in the treatment of AD from the mild stages. The most common
side effects are nausea, diarrhea, insomnia, fatigue, muscle cramps, and anorexia
(Schatzberg et al., 2010). For the moderate stage of AD, the N-methyl-D-aspartate
(NMDA) receptor antagonist memantine is a well-established mono-therapy (Gauthier &
Molinuevo, 2013). Memantine was approved in 2003 to treat the moderate to severe
stage of AD. This antagonist is thought to mitigate toxicity resulting from increased
calcium flow into neurons by blocking NMDA receptors (Schatzberg et al., 2010). When
NMDA receptors are blocked the neurodegenerative effects resulting from lower
glutamate levels and increased calcium influx in AD are reduced. This drug has been
quickly adopted in clinical practice because it is benign. In clinical trials, memantine’s
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rate of side effects is no different than the rate with placebos--side effects may include
dizziness, confusion, headaches, and hallucinations.
Schatzberg et al. (2010) explained that moderate to severe AD patients, who take
memantine, appear to have more improved cognition and activities of daily living
(ADLs) than those who take placebos. Importantly, memantine also modestly reduces the
time that caregivers must spend with an Alzheimer’s patient. In addition, AD patients
who are already taking donepezil appear to improve when memantine is added to their
regimen (Schatzberg et al., 2010). ChEIs and memantine have demonstrated symptomatic
efficacy in several clinical studies. To treat patients at the moderate to severe stage of
AD, who have lost their capacity for independent everyday living, a combination therapy
of both non-pharmacological and pharmacological therapy is used (Gauthier &
Molinuevo, 2013).
Combination Therapy
Gauthier and Molinuevo (2013) explained that AD symptoms become severe over
a period of years, which decreases the AD patient’s chances to meet physical, mental, and
daily needs. The authors suggest that combined therapy including both psychotherapy
and psychopharmacological therapy is necessary in the absence of a cure for AD. Due to
the fact that the disease may take up to a decade before it manifests itself, it is important
to seek and use treatments that may provide both immediate and sustained long-term
effects to slow the rate of clinical decline. Therefore, the use of combination therapy will
slow the progression of the disease process by treatment mirroring AD-- using
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cholinesterase inhibitors (ChEIs) such as donepezil, galantamine, and rivastigmine to
treat mild stages of AD and using the N-methyl-D-aspartate (NMDA) receptor antagonist
memantine to treat moderate and onward stages of AD (Gauthier & Molinuevo, 2013).
However, interventions that substantially affect the course of the disease or the quality of
life of Alzheimer’s patients appear to be some distance away (Schatzberg et al., 2010).
Summary
Alzheimer’s disease (AD) is the sixth leading cause of death in the United States.
It is the fifth leading cause of death in Americans over the age of 65 (AA, 2012). The
amyloid hypothesis is the leading theory that explains AD pathogenesis. Accumulation of
protein in the brain is the initial event in AD--amyloid plaques followed by
neurofibrillary tangle formation. AD is the most common form of dementia (AA, 2009).
The disease is degenerative, causing individuals to have memory loss, and changes in
reasoning, judgment, and behaviors.
AD is a disorder that primarily affects individuals 65 and older, individual’s
families, caregivers, government, third-party insurance agencies, academia, and the
scientific communities. A collaboration of all entities must come together to find a cure
or delay the progression of AD (NAPA, 2011). Brain imaging such as MRIs and PETs
are also helpful in diagnosing patients with AD. In addition, criteria based on the
NINCDS-AD&DA and use of clinical instruments to measure cognition and behavior
resulted in an accurate diagnosis for between 60 and 70% of patients having AD (Thomas
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& Fenech, 2007). However, presently, the only way to definitively diagnosis AD is
through brain autopsy (Handen et al., 2012).
Consistent risk factors for AD are age and sex (Kalaria et al., 2008; Perez et al.,
2012). Most individuals diagnosed with AD are over the age of 65 (LOAD) and are
women. Prevalence studies such as the Chicago Health and Aging Project (CHAP) and
the Aging Demographics and Memory Study (ADAMS) revealed that about two-thirds of
Americans with AD are women. Of the 5.2 million Americans older than 65 years with
AD, 3.4 million are women and 1.8 million are men. In addition, the ADAMS study
indicated that 16% of females over 71 years of age have AD compared to 11% of males.
Other risk factors include genetic association and risk genes such as APOE ε4 and
SORL1. In addition, stroke injuries, vascular diseases, type 2 diabetes, obesity,
hypertension, and decreased physical activity are also risk factors for AD (Bassil &
Grossberg, 2010; Mathis & Burke, 2009; Solfrizzi, et al., 2013).
Memory impairments and executive dysfunction are symptoms of AD.
Individuals will experience cognitive and behavioral problems such as depression,
agitation, and apathy (Wilson, Arnold, Beck, Bienias, & Bennett, 2008). Each stage of
the disease can have different symptoms or sometimes the stages will overlap (AA,
2013). Progression of AD does not consider age chronology. AD victims can experience
up to seven stages of the disease, starting from Stage 1, involving no impairment to Stage
7, which can include very severe cognitive impairment (AA, 2013).

54
The CMS and the AA are agencies that recommend assessment and screening
tools to medical and clinical professionals for the diagnosis or detection of dementia/AD
(Furiak, 2012). Most developed nations agree that early screening conducted on patients
with a high risk potential will allow patients, family members, and caregivers to initiate
planning and preparation for long-term financial and social well-being to prepare for
training, stress management, and on-going care (Furiak, 2012).
Treatment of AD can be delivered via psychotherapy, pharmaceutical therapy, or
a combination of both. There is a great deal of collaboration by the government, public,
and private sectors to find a cure for AD (Gauthier & Molineuvo, 2013; Khawli &
Prabhu, 2013; Logsdon et al., 2007). The NAPA (2011), which is a research initiative
implemented by The Obama Administration, spearheaded additional interest and
awareness of AD and commitments to find a cure. Continual sharing of information and
financial support from the government and private sectors are necessities headed in the
right direction to prolong/put an end to the sixth leading cause of death among 65 year
olds and beyond. In addition, the increasing population of baby boomers will also be at
risk for contracting AD (AA, 2013), which is another critical reason to compare
symptoms and stages of EOAD patients to that of LOAD patients.
The above occurrences have led researchers to the facts that AD patients can and
do go through various stages and symptoms of this degenerative disorder (AA, 2013;
Gauthier & Molinuevo, 2013; Reisberg, 2013; Wilson et al., 2008). There was a gap in
literature that did not focus on caregiver perspectives of what they viewed when caring
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for AD patients while the AD patients were experiencing various stages and symptoms of
the disease. Chapter 3 focused on research questions, methodology, participant protection
and rights, instrumentation, and data collection and analysis, which provided a roadmap
or foundation to explore and determine possible future progress treatment plans,
incentives and psychological interventions for AD.
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Chapter 3: Research Method
Methodology
AD is defined as development of multiple cognitive deficits evidenced by
memory impairment or cognitive disturbances that may or may not include the following:
language disturbance, inability to carry out motor activities, failure to recognize objects,
or the loss of executive functioning. In addition, these multiple cognitive deficits may or
may not cause significant impairment in social or occupational functioning and represent
a significant decline from previous functioning levels (APA, 2013).
AD is the fifth leading cause of death among Americans ages 65 and older (AA,
2012). Although multiple research entities have formed collaborative efforts to prolong
life with the disease or provide treatment interventions, there is no known cure for AD
(NAPA, 2011).
Over the past 150 years, advances in the treatment of heart disease and cancer
have contributed to increased life expectancy and a marked change in aging biodemographics. In addition, general improvements in public health and medical care
during the 20th century, such as advances in laboratory techniques and technology,
investments in disease surveillance, regulation of tobacco products, screening of
newborns for metabolic and other heritable disorders have added increased life
expectancy (Carrillo et al., 2013; CDC, 2011). As a result, the principal causes of death
have shifted dramatically from chiefly infectious diseases to cardiovascular disease,
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cancers, and increasingly, progressive neurodegenerative dementias, such as AD (Kling,
Trojanowski, Wolk, Lee, & Arnold, 2013).
AD is the most common form of dementia (AA, 2009). Those commonly
affected by AD are individuals ranging from age 65 years to 85 years. This group will
most likely include a significant number of future baby boomers, since they began
turning 65 in 2011. It has been estimated that by the year 2050 the rising cost to treat this
population will be $1 trillion or more (Okie, 2011). AD patients have also been known to
have different symptoms at different stages of the disease. Due to the fact that stages can
and do overlap, it is hard to place individuals in any one stage of AD (AA, 2013).
Therefore, comparing symptoms between EOAD patients and LOAD patients offers
further insight into ways to generate treatment/intervention plans, to slow the progression
of the disease, or perhaps find a cure for this disorder.
Research Design and Rationale
Chapter 3 described the methodological approach including the mixed-method
research design, setting, and participants. The mixed-method design was a combination
of qualitative and quantitative components, including an inductive approach, using
personal perspectives together with statistical inferences. Chapter 3 also included and
described instruments used to acquire and analyze data. Process descriptions of ethical
requirements were presented in this chapter as well. The research questions answered in
this study were as follows:
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Research Question and Hypotheses
RQ1: Are there differences in cognitive symptoms between EOAD patients and LOAD
patients?
H01: EOAD patients have the same cognitive symptoms as LOAD patients.
Ha1: EOAD patients have different cognitive symptoms than LOAD patients.
RQ2: Are there differences in behavioral symptoms between EOAD patients and LOAD
patients?
H02: EOAD patients have the same behavioral symptoms as LOAD patients.
Ha2: EOAD patients have different behavioral symptoms than LOAD patients.
Mixed Method Approach
A quantitative review was conducted, using a demographic background survey, in
order to obtain information from caregivers who provided care to AD patients who had
EOAD or LOAD. These caregivers supplied answers to questions that determined the
particular stage level of the AD patient. Quantitative instruments, the BEHAVE-AD
(Reisberg, et al., 1987) and the Short IQCODE (Jorm, 1994) were used to gain empirical
evidence of the AD patient’s behavior, which were filled out by the caregiver. A
qualitative interview preceded caregivers filling out quantitative measures such as the
BEHAVE-AD and the Short IQCODE. As a result, this research design is both
quantitative and qualitative in nature, using a sequential mixed method approach.
Creswell (2009) indicated that quantitative research is a means for testing
objective theories by examining the relationship among variables. The variables can then
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be measured, usually on instruments, so that numerical data can be examined utilizing
statistical processes. Creswell (2009) defined qualitative research as a means for
understanding and exploring a social or human problem through the perspectives of
groups or individuals. The research process involved emerging questions and procedures,
collecting and analyzing data, building from specific to general themes, and making
interpretations of data meaning.
Storandt, Balota, Aschenbrenner, and Morris (2014) described the clinical,
cognitive, and personality characteristics of 249 participants in a multinational
longitudinal study of autosomal dominant Alzheimer’s disease (ADAD). Participants
were from ADAD families with mutations in 1 of 3 genes (APP, PSEN1, or PSEN2). The
authors compared cognitively normal mutation carriers, cognitively normal mutation
noncarriers, and very mildly impaired mutation carriers using mixed model analyses.
Results revealed that global cognitive deficits like those observed in late-life sporadic AD
exist in mild ADAD compared with cognitively normal carriers and noncarriers on all but
two measures of Storandt et al. (2014) concluded that cognitive and personality deficits,
overall, in very mild ADAD are similar to those seen in sporadic AD and cognitive
deficits also took place in asymptomatic mutation carriers who were nearer the age of
dementia onset.
Participants and Sample Size
My introduction to the Alzheimer’s Association was facilitated by the Chief
Program Director of the Houston Southeast Chapter via letter of cooperation (see
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Appendix C). This individual provided me access to Alzheimer’s caregiver group
locations throughout the Houston area and surrounding towns. I distributed flyers
throughout the Houston Southeast Chapter Alzheimer’s Association locations
inviting/recruiting caregivers to participate (see Appendix K). I had no relationships with
the Chief Program Director or any of the Alzheimer’s Association group participants. I
recruited participants from various caregiver groups, who were members of the
Alzheimer’s Association, Houston Southeast Chapter, and provided care to individuals
who had been diagnosed with AD according to criteria in the DSM-V (APA, 2013). The
study included a qualitative aspect, which consisted of caregivers answering interview
questions related to operational constructs such as cognitive/behavioral symptoms of AD.
Grounded theory was the research tool I used to seek out and understand potential
social patterns and structures of Alzheimer’s disease through the process of constant
comparison. Grounded theory generally reflects the participant’s own interpretations or
coming from their own perspectives, rather than being introduced or imposed by the
investigator (Coleman, 2006). In qualitative research, the number to reach action or
grounded theory is between 5 and 20 (Patton, 2001). The process of grounded theory
involved using multiple stages of data collection and the interrelationship of categorical
information. I compared data with emerging categories and sampling of different groups
to maximize the similarities and differences of information.
Beard, Sakhtah, Imse, and Galvin (2012) investigated dyads where one spouse
had been diagnosed with memory loss. The authors conducted in-depth qualitative

61
interviews with 10 couples (N=20). Beard et al. (2012) used grounded theory approaches
to collect, code, and analyze data into data themes. The authors found that community
services and care practices were insightful to ways that couples organized and prioritized
their relationship prior to diagnosis in order to encourage positive care patterns between
them, foster successful adaptation changing needs of the couple, and support in-home
arrangements for as long as possible.
During my research study, the caregivers received a background demographic
questionnaire from me to complete (See Appendix D) on behalf of the individuals that
they cared for with AD N = 20. There were two groups for the duration of illness
comparison and behavioral/cognitive symptoms/changes. Group I (n = 8) consisted of
EOAD patients (younger than age 65) and Group II (n = 12) consisted of LOAD patients
(older than age 65). I used demographic survey screening to obtain each group. Preceding
the quantitative portion of the study, six of the total caregivers received from me a
qualitative interview to gain their perspectives of what they observed the AD clients
experiencing in regards to behavioral and cognitive changes.
Participant Protection and Rights
The caregivers were the sole source of information on behalf of the patient sample
in this study. I explained informed consent and confidentiality to caregivers. They were
informed that their participation in the research was voluntary, without any
compensation; and at any time during the research they could withdraw without any form
of penalty. I protected the rights of all participants as per certification of the National
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Institute of Health training course (See Appendix J). In addition, I adhered to questions
from the standard demographic background questionnaire (See Appendix D), both
informant questionnaires (See Appendices E and F), a qualitative interview (Appendix G)
to gain caregiver perspectives of the cognition and behavior of AD clients, and
caregivers/participants were not coerced in any way through use of personal biases.
Materials such as questionnaires and statistical instruments were coded with numbers and
kept in a secured area inside a locked file cabinet. I used email addresses and phone
numbers to communicate with participants. Once the research study was completed I
locked all materials and secured them in a locked file cabinet to be kept for 5 years. After
the 5 years I will destroy the material by shredding it. Upon completion of my study, all
participants were debriefed via telephone/email. I also provided participants with
summary results of the study and how it would benefit others living with or caring for
those with AD in the future.
Instrumentation
Participants were given sufficient information about the study. Once caregivers
acknowledged that they understood it well enough to make an intelligent decision
concerning whether or not they wanted to participate, I administered the structured
demographic questionnaire (see Appendix D) via telephone. If the caregiver had care
recipients who met criteria as reflected in the demographic questionnaire, then I asked
them to participate in completing the BEHAVE-AD informant form (see Appendix E)
and the Short IQCODE (see Appendix F). I administered the BEHAVE-AD and the
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Short IQCODE informant instruments via telephone to the caregiver to obtain
information regarding the individual they were providing care for. I used these
instruments to assess cognitive, behavioral and general clinical symptoms of the AD
patient. I used the BEHAVE-AD and the Short IQCODE assess behavioral and cognitive
symptoms separately so as not to result in a so-called halo effect, meaning that the rating
of one area, e.g.: behavioral, can influence rating of another area, e.g.: cognition. It is
usually advantageous that assessment of behavioral symptoms and cognitive evaluation
be separately measured or performed with different instruments in research (Auer,
Monteiro, & Reisberg, 1996). Prior to the caregivers completing the behavioral and
cognitive informant form on behalf of AD patients (N= 20), the qualitative interview (see
Appendix G) was conducted. I chose six of the participating caregivers to take part in the
qualitative interview process. I scored the informant questionnaires using the SPSS
Software, and the qualitative interview (see Appendix G) was organized and evaluated by
hand. I provided definitions of the stages of AD to each respondent via the background
demographic questionnaire (see Appendix D) to help them categorize their care
recipient’s status.
Demographic Questionnaire
The background demographic questionnaire (see Appendix D), which is a
standard survey questionnaire, was used to gain the necessary background
information/criteria (Bivin, 2013). It consisted of a 13-item self-report questionnaire. It
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provided age, gender, age at which AD patient was diagnosed, socioeconomic status,
education level, and stage of the disease.
Behavioral Pathology in Alzheimer’s Disease Rating Scale
The Behavior Pathology in Alzheimer’s disease Rating Scale (BEHAVE-AD) is
composed of 25 symptomatic items describing behavioral disturbances (Reisberg, et al.,
1987). This instrument covers symptoms in seven categories: paranoid and delusional
ideation, hallucinations, activity disturbances, diurnal rhythm disturbances,
aggressiveness, affective disorders and anxieties, and phobias (Robert, 2010; Auer,
Monteiro, & Reisberg, 1996). The BEHAVE-AD scale takes approximately 20 minutes
to administer (Robert, 2010). The behavior is rated as mild, moderate, or severe. The
instrument evaluates the importance of each of the 25 symptoms in the seven categories
using a 4-point severity scale with a score of “0” indicating that the item is not present; a
score of “1” indicating present of the symptom; a score of “2” indicating the symptom is
present, generally including an emotional component; and a score of “3” indicating the
symptom is present, generally with an emotional and physical component. The total
BEHAVE-AD scores range from 0 to a maximum score of 75. A global scale rating is
obtained of the degree to which these symptoms are troubling to the caregiver/informant
and/or dangerous to the patient (Reisberg et al., 2014; Robert et al., 2010; Auer,
Monteiro, & Reisberg, 1996).
I received permission to use the BEHAVE-AD Informant Scale via email from
Barry Reisberg, MD, at NYU Alzheimer’s Disease Center, New York University
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Langone Medical Center, New York on March 11, 2015 (see Appendix H). Dr.
Reisberg’s condition for the scale utility was that it be properly referenced and the
copyright noted in all reproductions. The BEHAVE-AD Informant was chosen because it
is an informant-based rating scale and was developed to elicit information obtained from
caregiver reports (Auer, Monteiro, & Reisberg, 1996). It assesses behavioral symptoms in
AD patients, independent of comparatively difficult to treat cognitive symptoms (Robert
et. al, 2010). This instrument had limitations because it was used to evaluate AD patients
based solely on information from their caregivers (i.e., spouses, children, parents).
Nonetheless, the instrument had good reliability in discriminating and good validation in
AD cases, whether non-pharmacological or pharmacological (Reisberg et al., 2014).
Short Informant Questionnaire on Cognitive Decline in the Elderly
The Short Informant Questionnaire on Cognitive Decline in the Elderly
(IQCODE) is a subjective rating scale that measures cognitive decline from a pre-morbid
level using informant reports (Jorm, 1994). The instrument was developed by Professor
Anthony Jorm in 1994 as a brief version of the IQCODE developed by Jorm and Jacomb
in 1989. I sent Dr. Jorm’s an email to inform him that I would be using this tool (see
Appendix I). The Short IQCODE is used to assess cognitive decline and dementia in the
elderly. The informant or caregiver is required to have known the elderly individual for
ten years or longer in order to provide information that compares his/her present
performance with 10 years ago. The questionnaire takes about 15 minutes. The score for
each question is summed and then divided by the number of questions, which are 16 for
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the Short IQCODE (Jorm, 1994). The range of scores is from 1 to 5 compared with 10
years ago how is his/her performance. A “1” indicates much improved, “2” a bit
improved, “3” not much change, “4” a bit worse, and “5” much worse. The Short
IQCODE (Jorm, 1994) was chosen because it has been proven to be useful for
individuals who are unable to undergo direct-cognitive testing due to acute illness, lack of
cooperation or death. Furthermore, this tool is also valuable in screening populations with
low education and literacy levels. Although the Short IQCODE (Jorm, 1994) was
developed for self-completion by informants, it has been and can be used as a face-toface or telephone interview. Another variation involves the 10-year time frame. A
number of users have found difficulty in finding informants/caregivers who possess the
required contact with the subject for over 10 years. As a result, this has led to the
modification of a 5-year time frame, which was the time frame for this study.
The Short IQCODE (Jorm, 1994) has high reliability. It measures a single general
factor of cognitive decline and validly reflects past cognitive decline, performs at least as
well as conventional cognitive screening test for dementia. Studies have also compared
the IQCODE to neuropathological diagnosis (Rockwood et al., 1998; Thomas et al.,
1994). This instrument was significantly correlated with 130 kDa amyloid precursor
protein in AD patients’ blood (Thomas, 1996).
Qualitative Interview
The qualitative interview (see Appendix G) consisted of two questions. The first
question allowed caregivers to give their perspectives of what memory/behavioral
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changes they had observed in their AD care recipients over the past 2 to 5 years. The first
question had eight subcategories that were semi-structured. The second question allowed
the caregiver participants to be more general and explain more in detail what they viewed
as memory/behavioral changes. These qualitative interview questions were chosen to
explore more detail of what the caregivers observed in their shared experiences with the
AD population.
Data Collection and Analysis
As mentioned prior, I presented a background demographic questionnaire to
caregivers from various Alzheimer’s Association caregiver group locations throughout
Houston and surrounding areas. This particular questionnaire included demographic
questions about AD care recipients’ age, gender, socioeconomics, meeting DSM-V
criteria for AD, age at which AD diagnosis was made, stage of the disease, as well as the
age, length of time caregiver had known care recipient, and the relationship of caregiver
to AD care recipient (i.e., spouse, adult child, parent, other). Once, this stage of the
process had been completed, caregiver participants were asked to complete the
BEHAVE-AD and Short IQCODE Informant Report Forms, as well as provide narratives
on the cognitive/behavioral changes they had viewed in the AD care recipients through
use of a structured qualitative interview. Both instruments took approximately 45 minutes
to administer.
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Quantitative Analysis
I used the analysis of variance (ANOVA) for statistical analysis. ANOVA is a
hypothesis-testing procedure to estimate mean differences between two or more
populations (Gravetter & Wallnau, 2009). Onset of diagnosis (EOAD or LOAD) was
analyzed as a between subject variable. Scores on the BEHAVE-AD and Short IQCODE
were treated as dependent variables. Alpha was set at 0.05. Statistical analysis drawn
from the sample data (survey answers supplied from the caregiver and symptoms
endorsed from research instruments) revealed the most salient memory/behavioral
symptoms, whether patients were of EOAD or LOAD. The prediction after the
BEHAVE-AD and the Short IQCODE were scored—summing up totals of caregiver
answers—yield quantitative measures of memory/behavioral symptoms that were
compared to onset of AD and determined appropriate stage levels, and used with caution
to generalize to other AD victims. Symptoms on the BEHAVE-AD and the Short
IQCODE were scored using version 21 of the SPSS program.
Qualitative Analysis
Grounded theory has been described as “the most influential paradigm for
qualitative research in the social science arena today” (Patton, 2002). Grounded theory
originated out of the collaboration of Glaser and Strauss (1967), who developed a
methodological approach based on the theory of symbolic interactionism between 1920
and 1950. This sociological approach posited fluid and dynamic interpersonal processes
in which meaning was created within and derived from social interactions (Kendall,
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1999). Grounded theorists cross-examined the meanings created in these social
relationships by trying to discover how these groups of individuals defined their realities
based on their understanding of interpersonal interactions (Cutcliffe, 2000), which is why
I am using this theory.
I conducted face-to-face/phone interviews in participants’ homes, business/facility
conference rooms, and public libraries, using grounded theory to gain information that
gave each caregiver’s perspective. Two open-ended questions were given to 6 of the 20
participating caregivers by me after I had built and established rapport (see Appendix G).
I analyzed qualitative data using Braun and Clark’s (2006) six-phase thematic analysis:
1) data was gathered/collected from observational data, questionnaire and interview
statements, and audio recording; 2) data were coded by hand, every two to three lines of
text was coded with handles identifying key words, concepts, and reflections; 3) codes
were validated by reading and re-reading the data to integrate codes in order for themes
to emerge; 4) themes were reviewed, defined, and refined; subthemes were formed; and
eventually this step allowed patterns to emerge from the data; 5) themes were named and
descriptions written in order to help communicate meaning to readers; and 6) a datadriven report was written, making an argument in relation to the research question(s),
hopefully, convincing the reader of its merit and validity of the analysis. I also included
these steps in an inductive approach.
For example, when each caregiver had: (a) provided me their interpretation,
answers, and understanding of the two interview questions; (b) provided me
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clarification/elaboration of the two interview questions, tape/audio recordings, notes and
memos; then (c) I evaluated and compared each caregiver statements and answers my
final quantitative results. This was done to obtain trustworthiness, which involved
credibility, transferability, dependability, and confirmability (Lincoln & Guba, 1985).
Lincoln and Guba (1985) suggested that trustworthiness is the standard by which
a qualitative study can be judged. The authors explained that the central organizing
principle, trustworthiness, was linked to standards applied to quantitative studies such as
validity, reliability, generalizability, and objectivity. There was a series of techniques that
Lincoln and Guba (1985) mentioned that I used to evaluate qualitative data analysis such
as establishing credibility, transferability, dependability, and confirmability.
Furthermore, the additional narrative themes that became salient from qualitative
interviews, I received from caregivers, can and will shed light on present and future
treatment plans and/or preventive measures for AD.
Summary
Over the past 150 years, advances in the treatment of heart disease and cancer are
responsible for postponement of mortality and a marked change in aging biodemographics. In addition, improvements in public health and medical care during the
20th century led to considerable increases in life expectancy (Carrillo et al., 2013). As a
result, the principal causes of death have shifted dramatically from chiefly infectious
diseases to cardiovascular disease, cancers, and increasingly, progressive
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neurodegenerative dementias, in this case, Alzheimer’s disease (Kling, Trojanowski,
Wolk, Lee, & Arnold, 2013).
AD is the fifth leading cause of death among Americans age 65 and older (AA,
2012). In order to conduct research on human subjects (caregivers), I considered ethical
issues such as informed consent, privacy, confidentiality, and authorization to disclose
PHI. I presented these forms to caregivers on behalf of the AD care recipients. In
addition, to keep participants safe from harm, I addressed this through participant
protection and rights.
The methodological approach I used to examine symptoms and stages of AD
among participants (EOAD and LOAD patients) was a mixed method design (Creswell,
2009). I recruited participants from Alzheimer’s Association caregiver groups across the
Houston Metropolitan and surrounding areas. I used the following instruments to study
and obtain new information and details about AD: (a) the BEHAVE-AD Informant
Report form (Appendix E); (b) the Short IQCODE (Appendix F); (c) the qualitative
interview (Appendix G); and (d) the demographic background questionnaire (Appendix
D). Once I scored the quantitative instruments through the SPSS program; reached
saturation for themes and subthemes from qualitative interview questions; and integrated
both approaches, I obtained detailed results and analyses that are provided in Chapter 4.
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Chapter 4: Results
Introduction
The purpose of this mixed-method study was to determine whether or not
individuals with EOAD or LOAD experience different behavioral and cognitive
symptoms, using caregivers as informants. For the qualitative analysis, a qualitative,
semi-structured interview was used to understand the experiences of caregivers, who
gave personal perspectives of what they observed while caring for an individual who had
been diagnosed with EOAD or LOAD. Each interview was audio-taped and then
transcribed verbatim and coded and categorized in order to create successful, thematic
outcomes.
For the quantitative analysis, behavioral symptoms were measured by having
caregivers fill out the BEHAVE-AD informant questionnaire and the Short IQCODE
informant questionnaire for memory symptoms. The independent variable was type of
diagnosis (EOAD vs. LOAD). The dependent variables were behavioral and memory
symptoms. I conducted a one-way ANOVA analysis to determine if differences existed in
behavioral and memory symptoms between early- versus late-onset AD individuals. This
chapter will restate the purpose of the study as well as research questions and hypothesis.
It will discuss the setting, demographics, data collection process, as well as report data
analysis and results describing the qualitative components followed by the quantitative
components.
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Research Questions and Hypotheses
RQ1: Are there differences in cognitive symptoms between EOAD patients and
LOAD patients?
H01: EOAD patients have the same cognitive symptoms as LOAD patients.
Ha1: EOAD patients have different cognitive symptoms than LOAD patients.
RQ2: Are there differences in behavioral symptoms between EOAD patients and
LOAD patients?
Ho2: EOAD patients have the same behavioral symptoms as LOAD patients.
Ha2: EOAD patients have different behavioral symptoms than LOAD patients.
Demographic Samples and Data Collection
I used the Alzheimer’s Association’s Houston Southeast Chapter to recruit
participants from various caregiver support groups. Criteria included that caregivers were
age 18 and older, and cared for someone who had been diagnosed with AD before the
age of 65 (EOAD) or after the age of 65 (LOAD). The diagnosis of AD had to be
according to criteria in the DSM-V (APA, 2013). Flyers were either posted or handdelivered by me to various caregiver support facilities throughout the Houston
metropolitan area and other surrounding cities and towns (League City, Clear Lake,
Pasadena, Texas City, Pearland, Missouri City, Sugar Land, Bellaire, Memorial, Lake
Jackson, and Conroe). Caregivers acted as informants on behalf of the individuals who
had been diagnosed as EOAD or LOAD.
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Between October 12, 2015 and March 16, 2016, I presented caregiver participants
with research packets after they had agreed to participate in the study. Caregiver
participants contacted me by cell phone or in person after support group meetings.
Research packets for the qualitative component of the study took 30 to 45 minutes to
complete, and consisted of informed consent forms, demographic questionnaires and
qualitative, semi-structured, open-ended interview questions.
Research packets for the quantitative component of the study took about 45
minutes to an hour to complete and consisted of informed consent forms, demographic
questionnaires and two quantitative measures: a) the BEHAVE-AD informant survey,
used to measure behavioral symptoms, and b) the Short-IQCODE survey, used to
measure cognitive/memory symptoms. Due to the mixed method nature of this study, I
used a sequential design (qualitative component followed by the quantitative component).
Originally, 31 packets were passed out and sent to caregiver support group
facilities. Twenty (65%) of the 31 packets were returned. Study sample participants
(N =20) consisted of two groups: EOAD (n=8) and LOAD (n=12). This was a slight
deviation from the data collection plan I had hoped to pursue, which indicated counts (N=
26, which were (Group 1, n =13 participants and Group 2, n =13). Each participant in the
two groups was given a quantitative packet. Consent forms were explained in detail and
in person to participants. Before they signed and agreed to the study, they were asked if
they understood the details that were explained to them. After they indicated
understanding, consent forms were presented for their signatures. Six of the 20

75
individuals also participated in the qualitative component of the study. They were divided
into two groups: Group 1: EOAD (n=3) and Group 2: LOAD (n = 3). Group 1 consisted
of two men and one woman; Group 2 consisted of two women and one man.
The qualitative data collection process consisted of a face-to-face qualitative
interview, which consisted of two, open-ended questions with question one including
eight (8) short sub-questions. Each participant was audio recorded with a mini tape
recorder. Each interview was transcribed verbatim. The quantitative data collection
process consisted of participants either filling out packets in person, over the telephone,
or via the internet. Both qualitative and quantitative interviews were conducted in library
conference rooms, private offices, and in participant homes. Overall demographics for
this study are presented in Table 1.
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Table 1
Subject Demographics of Research Sample (N = 20)
Variable
English Speaking
Yes

%

N

100.0

20

AD Patient Age
59-69
70-79
80-94

35.0
30.0
35.0

7
6
7

Gender
Male
Female

35.0
65.0

7
13

Race/Ethnicity
Black/African American
Hispanic/Latino
White/Caucasian

40.0
5.0
55.0

8
1
11

Marital Status
Single
Married
Divorced
Widowed

10.0
55.0
5.0
30.0

2
11
1
6

Highest Level of Education
High school
Some college
College graduate
Post graduate degree
No school/college

15.0
35.0
30.0
15.0
5.0

3
7
6
3
1

Economic ($) Status of AD patient
1 to 4,999
5,000 to 19,999
20,000 to 49,000
50,000 to 69,000
100,000 and above
Declined to state

5.0
15.0
35.0
20.0
10.0
15.0

1
3
7
4
2
3

Primary Caregiver
Yes
No

85.0
15.0

17
3
(continued)
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Table 1. Subject Demographics (continued)
Variable
Relationship to care recipient
Spouse
Adult/Child/Grandchild
Other

%

N

35.0
40.0
25.0

7
8
5

35.0
65.0

7
13

5.0
5.0
30.0
15.0
35.0
10.0

1
1
6
3
7
2

Age at AD diagnosis
< 65 years
> 65 years
Patient’s Stage of AD
Stage 2
Stage 3
Stage 4
Stage 5
Stage 6
Stage 7
Note: N = 20; < = less than; > = greater than
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Data Analysis
Qualitative Component
I conducted the qualitative component before the quantitative component. This
sequence was done purposefully, in order not to taint caregiver informant answers to the
semi-structured, qualitative interview questions, which asked about behavioral and
cognitive changes in the care recipients. The questions were similar to those found on the
BEHAVE-AD and Short-IQCODE questionnaires, which were used in the quantitative
component of this study. Each caregiver participant told his/her personal perspective of
what behaviors/cognitive symptoms they observed in their loved ones or patients who
had EOAD/LOAD.
The six-phase thematic analysis (Braun & Clark, 2006) was the process used to
analyze the data. First, the six qualitative interviews were audio-taped and transcribed
verbatim. Second, each interview was read and coded by hand (identifying key words and
phrases). Third, interviews were read and re-read; comparisons were made to integrate
codes and to develop themes. Fourth, themes were labeled as well as subthemes leading
to various patterns. Fifth, themes were finalized upon reaching saturation. Sixth, themes
were analyzed to determine alignment with interview questions in order to produce the
analytical report. Once the data was coded by hand, the Maxqda program was not
necessary (as indicated in Chapter 3). However, by not using the Maxqda program, the
process took much longer.
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Participants’ narrative answers to the qualitative interviews questions resulted in
various codes such as: (a) short-term memory loss; (b) aphasia; (c) patterns of emotions
(i.e., from happiness to sadness, from jovial to withdrawn to openness, from scared to
crying to jovial); (d) spending and giving away money; (e) selling personal belongings
and property; (f) problem eating; (g) problem bathing: (g) problem putting on clothes;
(h) anxiety; (i) irritation; (j) frustration; (k) depression; (l) paranoia; (m) hallucinations;
(n) drug abuse; (o) alcohol abuse; (p) fighting; (q) biting; (r) cursing; (s) and screaming.
The primary themes were: (a) cognitive impairment; (b) mood swings; (c) impulsiveness;
(d) struggling with activities of daily living; (e) psychological behaviors; and (f)
maladaptive (adverse) behaviors. Further analysis is included in the results section of
qualitative component analysis (Table 2).
Quantitative Component
Table 1 indicated the demographic background of the quantitative component of
this study. The following research questions were answered after conducting quantitative
analysis through use of the SPSS software version 21.0 (IBM Corp. Released 2012).
RQ1: Are there differences in cognitive symptoms between EOAD patients and LOAD
patients?
H01: EOAD patients have the same cognitive symptoms as LOAD patients.
Ha1: EOAD patients have different cognitive symptoms than LOAD patients.
RQ2: Are there differences in behavioral symptoms between EOAD patients and
LOAD patients?
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Ho2: EOAD patients have the same behavioral symptoms as LOAD patients.
Ha2: EOAD patients have different behavioral symptoms than LOAD patients.
To answer RQ1, I gave caregiver participants the Short-IQCODE, which is a
subjective rating scale that measures cognitive decline from a pre-morbid level using
informant reports. Informants were required to have known the individual with
EOAD/LOAD for at least 5 years. The questionnaire took about 15 minutes to complete
with a total of 16 questions. The range of scores were from 1 to 5, with “1” indicating
much improved, “2” a bit improved, “3” not much change, “4” a bit worse, and “5” much
worse. The independent variable was type of diagnosis (EOAD vs. LOAD) and the
dependent variables were the outcomes of the 16 questions completed by participants on
the Short-IQCODE questionnaire. See (Table 3).
To answer RQ2, I gave each participant (caregiver) the BEHAVE-AD to fill out
on behalf of the AD patient (EOAD/LOAD). This tool measures 25 symptoms describing
behavioral disturbances in seven categories (Paranoid and Delusional; Hallucinations;
Activity Disturbances; Aggressiveness; Diurnal Rhythm Disturbance; Affective
Disturbances; and Anxieties and Phobias). The instrument evaluates the importance of
each of the 25 symptoms in the seven categories using a 4-point severity scale with a
score of “0” indicating symptom is not present; “1” indicating present of symptom; “2”
symptom is present with an emotional component; and “3” symptom is present with an
emotional and physical component. In addition, this instrument allows a global scale
rating to be obtained which describes the degree to which the behavioral symptoms are
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troubling to the caregiver and/or dangerous to the patient. It took 20 to 25 minutes to
administer the BEHAVE-AD questionnaire.
Results of Qualitative Component (Qualitative Interview Q1 and Q2)
Demographics of caregiver recipients: early-onset AD (EOAD) patients were 3 (2
men and 1 woman) and late-onset AD (LOAD) patients were 3 (1 man and 2 women).
The average age of caregiver recipients was 74 years. Half of the AD patients who were
being cared for by caregivers were Black/African American and the other half were
White/Caucasian. The primary and sub-themes that emerged out of the data are as
follows and also listed in Table 2. Caregiver informants were asked to elaborate on Q1:
Over the past 2 – 5 years, what are some of the things you observed about this person’s
change in memory/behavior and Q2: What are some of the most favorable/unfavorable
moments you have observed about this individual’s memory/behavioral changes?
Following are the primary themes that emerged from the interviews.
Primary theme 1: cognitive impairment: All of the caregiver informants described both
early- and late-onset AD patients as having short-term memory loss as well as aphasia.
One of the three EOAD patients was described as having long-term memory loss.
Primary theme 2: mood swings: All of the caregiver informants discussed emotional
patterns that they observed in each of the AD patients. One EOAD patient was described
as being frightened then began crying and then appeared to be jovial. Three (2 EOAD
patients and 1 LOAD patient) were described as being in a happy mood, then going from
sadness to jovial. Two LOAD patients were described as being jovial, then becoming
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withdrawn, and later appearing very open to teenagers or individuals they were
socializing/visiting with.
Primary theme 3: impulsiveness: All of the EOAD patients fell into this theme (category).
The sub-themes told of how each of the three went though a phase where they did a lot of
frivolous spending where they began spending money, giving away money, and selling
off personal belongings. By assessing the present stage of the disease (according to
Reisberg’s seven stages of Alzheimer’s) the caregiver informants reported the majority of
the EOAD group to be in stage 4. However, impulsive behaviors were reported to have
taken place even before the AD patients had been diagnosed.
Primary theme 4: struggles with activities of daily living: Caregiver informants stated
that 5 out of the 6 AD patients struggled with or needed help with eating,
bathing/showering, putting on clothes, brushing his/her teeth, and going to or using the
bathroom.
Primary theme 5: psychological behaviors: All of the caregiver informants indicated that
they observed their care recipients to have periods where they often went through
anxiousness, agitation, irritability, frustration, depression, paranoia, and sometimes
hallucinations, depending on the present state of the disease.
Primary theme 6: maladaptive (adverse) behaviors: One of the EOAD patients was
reported to have a history of drinking alcohol and using drugs. Many of the other
individuals in this qualitative study were observed by their caregivers to be aggressive at
times when they would fight, bite, kick, curse, or scream. These actions were reported to
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take place prior to the AD patient taking a bath/shower, staff members entering AD
patient’s room to help them with ADLs; or watching a television program.
As indicated in Table 2 the primary themes were: cognitive impairment, mood
swings, impulsivity, struggles with ADLs, psychological behaviors, and maladaptive
behaviors. Both EOAD participants #5, #6, #7 (EP5, EP6, EP7) and LOAD participants
#1, #2, #3 (LP1, LP2, LP3) were reported to have experienced cognitive deficits,
especially short-term memory.
Caregiver participants indicated that care recipients’ cognitive symptoms seemed
to get worse as the disease progressed. Caregiver informants used criteria for caregiver
recipient stage levels according to Reiberg’s seven stages of AD: LP1, LP2, and EP6
were in stage 6 and LP3, EP5, and EP7 were in stage 4 of the disease. In regards to
aphasia, the majority (2 out of 3) of LOAD caregiver recipients showed common
characteristics. Wandering seemed to play a role in the majority (2 out of 3) of EOAD
caregiver recipients. There was an equal number of EOAD and LOAD caregiver
recipients who experienced mood swings and half (2 out of 4) were in stage 4 and the
other half (2 out of 4) were in stage 6. The same held true for impulsivity (LP2 and EP6
were in stage 6; and EP5 and EP7 were in stage 4). The majority (3 out of 5) of caregiver
recipients who struggled with ADLs were in stage 6 of the disease. As far as
psychological behaviors, it appeared that both EOAD and LOAD caregiver recipients
experienced these behaviors at different stages of the disease, which was unlike the
cognitive deficits that got worse as progression of AD occurred. Maladaptive behaviors
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were experienced evenly among both EOAD (EP5 – stage 4) and LOAD (LP2 – stage 6)
care recipients. After comparison of data and emerging themes, the EOAD and the
LOAD group were both utilized to maximize similarities and differences, as outcomes
are presented in Table 2.
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Table 2
Primary and Sub-themes for Qualitative Analysis (Early- and Late-onset Participant)
Primary themes

Subthemes

Caregiver/participant extracted response (s)

Cog. Impairment S-term Memory loss LP1”She has almost virtually no s-term memory”
LP2 “Her s-term memory was basically non-existent”
LP3 “His s-term memory is pretty much non-existent”
EP5 “The next 5 or 10 minutes she don’t remember”
EP6 “No he don’t remember any of the birthdays”
EP7 “He would tell stories that were the same stories”
__________________________________________________________
LP1 “She can’t remember names or anything.”
LP3 “He doesn’t make full sentences”
EP7 “He will struggle with words and names”
__________________________________________________________
Aphasia

LP3 “He drove to the store and ended up walking back
EP5 “She was roaming trying to leave”
EP7 “He got lost in Dallas going to meet his brother”
______________________________________________________________________________
Wandering

Mood Swings Emotional Patterns LP1 “She goes from sadness to euphoria”
LP2 “It’s odd, like on a dime she’s from happy to mean”
EP5 “…5/10 minutes, pass she cries, she’s angry, scared”
EP7 “His mood is better, he is more jovial”
______________________________________________________________________________
LP2 “Several times/week she paid him $100 for the yard”
EP5 “It’s got to be high dollar, nothing cheap”
EP6 “He was selling off all equipment, spending freely”
Decision-making
EP7 “Gave daughter permission to visit w/o recollection”
______________________________________________________________________________
Impulsivity

Frivolous Spending

LP1 “They feed her and put her in wheel chair”
LP2 “It’s harder for her to keep up with eating, bathing”
LP3 “He needs help as far as grooming, bathing, eating”
EP6 “He don’t (eating, dressing) I take care of all of that”
EP7 “He has lack of understanding of the shower”
______________________________________________________________________________
Struggles with ADLs

(continued)
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Table 2. Primary and Sub-themes for Qualitative Analysis (continued)
Primary themes

Subthemes

Psychological Behaviors

Caregiver/participant extracted response (s)
LP1 “Yea, she gets irritated”
LP2 “Starting to get more agitated and more frustrated
LP3 “He gets frustrated a lot. The look on his face”

EP5 “The voice, the behavior, she is very agitated”
EP6 “They have him on medicine for his depression”
EP7 “He started actively hallucinating the last 3 months”
______________________________________________________________________________
Maladaptive Behaviors Aggression LP2 “Started getting more combative with staff”
EP5 “She was whipping their behinds up there (staff)”
______________________________________________________________________________
Notes: S-term = short-term; EP5, EP6, EP7 = EOAD participant #; LP1, LP2, LP3 = LOAD participant #;
ADLs = activities of daily living

Results of Quantitative Component (Research Questions 1 & 2)
Results of the quantitative-component analysis in this study are summarized in
Tables 3-11. RQ1 asked if there are differences in cognitive symptoms between EOAD
patients and LOAD patients. Table 3 describes mean differences for EOAD and LOAD
patients when it comes to cognitive symptom scores using a one-way ANOVA. In
regards to EOAD and LOAD patients when it came to separate cognitive symptoms alpha
was set at .05. There were no statistically significant differences in cognitive symptom
between EOAD (n = 8) and LOAD (n = 12) groups.
Table 4 describes Total Cognitive Symptom Scores. Results indicate that there
were no statistically significant differences in total cognitive symptom scores between
EOAD and LOAD groups, F (1, 18) = 1.019, p = .326, 2 = 0.05.
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Table 5 describes the assumption of variances using Levene’s test of equality of
variances. This test was used to determine whether variances between EOAD and LOAD
groups for cognitive symptoms are equal. Six of the 16 separate cognitive symptoms
were statistically significant (which indicates violation of the assumption of
homogeneity). This included the following: Remembering things that happened recently,
p = .005; Recalling conversation a few days later, p = .005; Remembering his/her address
and phone number, p = .005; Knowing how to work familiar machines, p = .028;
Handling money for shopping, p = .017; and using his/her intelligence to understand, p =
.028. The assumption of homogeneity of variances was violated, as assessed by Levene’s
test for variances. However, looking at the bottom of Table 5, when overall (total)
cognitive scores were analyzed for EOAD (n= 8) and LOAD (n = 12), the Levene’s test
is not statistically significant or the group samples were drawn from populations with the
same variance. Therefore, there was homogeneity of variances, as assessed by Levene’s
test for equality of variances (p = .184).
Table 6 provides descriptive statistics for cognitive symptom scores between
EOAD and LOAD care recipients. Mean score for EOAD was 78.3750 (SD = 2.77) and
mean score for LOAD was 75.75 (SD = 6.94). Total cognitive scores for EOAD had a
range from 72-90 and cognitive scores for LOAD had a range from 56-80, indicating
lower cognitive scores than the counterpart. According to the Short IQCODE
questionnaire, caregiver participants reported EOAD caregiver recipients as having
higher cognitive scores than LOAD caregiver recipients.
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Table 7 provides descriptive statistics for behavioral symptom scores of the
BEHAVE-AD tool. The mean score for EOAD was 19.25 (SD = 21.37) and the mean
score for LOAD was 11.08 (SD = 11.86). Total behavioral scores for EOAD care
recipients ranged from 0-69; whereas, the Total behavioral symptom scores for LOAD
caregiver recipients ranged from 2-45; again LOAD caregiver recipients indicate lower
behavioral symptom scores.
Table 8 summarizes the one-way ANOVA comparing means between EOAD and
LOAD patients with behavioral disturbances. Simply looking at p-values, there is only
one indication of behavioral significance between groups (Activity Disturbances), F (1,
18) = 5.858, p = .026, 2 = 0.25 indicating LOAD caregiver recipients scored higher on
Activity Disturbances.
Although Table 8 showed at least one mean difference among the group, Table 9
summarized specific behavioral differences in groups using the Test of homogeneity of
variances. The Levene’s test was statistically significant and showed that at least two of
behavioral disturbances violated the assumptions of homogeneity and showed that two of
the dependent variables (Aggressiveness: p = .044; and Anxieties and Phobias: p = .032)
between groups were not equal. However, Table 10 indicates that overall results for total
behavioral symptom scores using the one-way ANOVA reveal that the symptom scores
or the differences between the symptoms for AD caregiver recipients were not
statistically significant. Therefore, there was no evidence to reject the null hypothesis.
There are no differences between EOAD and LOAD behavioral symptoms. This is also
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indicated in Table 11 where the Levene’s test showed overall behavioral symptom scores
were not statistically significant indicating that the assumption of homogeneity of
variances is met. The Levene’s test of equality of variances tests the null hypothesis that
the population variances are equal. In other words, the group samples are drawn from
populations with the same variance. Finally, there were no statistically significant
differences in behavioral symptom scores between EOAD and LOAD groups, F (1, 18),
1.215, p = .285.

Table 3
Analysis of Variance (Cognitive Symptoms)
___________________________________________________________________________________
SS
df
MS
F
Sig.
___________________________________________________________________________________
Remembering things about family
Between Groups
.208
1
.208
.677
.421
Within Groups
5.542
18
.308
Total
5.750
19
_________ __________________________________________________________________________
Remembering recent things

Between Groups
.300
1
.300
2.400
.139
Within Groups
2.250
18
.125
Total
2.550
19
____________________________________________________________________________________

Recalling conversations days later

Between Groups
.300
1
.300
2.400
.139
Within Groups
2.250
18
.125
Total
2.550
19
____________________________________________________________________________________
Remembering his/her address

Between Groups 1.200
1
1.200
4.320
.052
Within Groups
5.000
18
278
Total
6.200
19
____________________________________________________________________________________
Remembering what day it is

Between Groups
.000
1
.000
.000
1.000
Within Groups
3.750
18
.208
Total
3.750
19
____________________________________________________________________________________
(continued)
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Table 3. Analysis of Variance (continued)
___________________________________________________________________________________
SS
df
MS
F
Sig.
___________________________________________________________________________________
Remembering where things are kept

Between Groups
.075
1
.075
.220
.644
Within Groups
6.125
18
.340
Total
6.200
19
____________________________________________________________________________________
Remembering where to find things

Between Groups
.075
1
.075
.432
.519
Within Groups
3.125
18
.174
Total
3.200
19
____________________________________________________________________________________
Knowing how to work fam. machines Between Groups
.408
1
.408
1.269
.275
Within Groups
5.792
18
.322
Total
6.200
19
____________________________________________________________________________________
Learning to use a new gadget/machine Between Groups
.133
1
.133
.655
.429
Within Groups
3.667
18
.204
Total
3.800
19
____________________________________________________________________________________
Learning new things in general

Between Groups
.033
1
.033
.655
.429
Within Groups
.917
18
.051
Total
.950
19
____________________________________________________________________________________
Following a story in a book or on TV

Between Groups
.000
1
.000
.000
1.000
Within Groups
5.750
18
.319
Total
5.750
19
____________________________________________________________________________________
Making decisions on everyday matters Between Groups
.133
1
.133
.655
.429
Within Groups
3.667
18
.204
Total
3.800
19
____________________________________________________________________________________
Handling money for shopping

Between Groups
.300
1
.300
1.271
.274
Within Groups
4.250
18
.236
Total
4.550
19
____________________________________________________________________________________
Handling financial matters

Between Groups
.133
1
.133
.655
.429
Within Groups
3.667
18
.204
Total
3.800
19
____________________________________________________________________________________
Handling other arithmetic problems

Between Groups
.033
1
.033
.084
.776
Within Groups
7.167
18
.398
Total
7.200
19
____________________________________________________________________________________
(continued)
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Table 3. Analysis of Variance (continued)
___________________________________________________________________________________
SS
df
MS
F
Sig.
___________________________________________________________________________________
Using intelligence to understand reason Between Groups
.408
1
.408
1.269
.275
Within Groups
5.792
18
.322
Total
6.200
19
____________________________________________________________________________________
Note: SS = sum of square; df = degrees of freedom; MS = mean squared; F = F-ratio; Sig. = p-value

Table 4
Total Cognitive Symptom Scores
______________________________________________________________________
SS
df
MS
F
Sig._
Between Groups
33.075
1
33.075
1.019 .326
Within Groups
584.125
18
32.451
Total
617.200
19
______________________________________________________________________
Note: SS = sum of squares; df = degrees of freedom; MS = mean squared; F = F-ratio
Sig. = p-value.

Table 5
Test of Homogeneity of Variances
_____________________________________________________________________
Levene Statistic
df1
df2
Sig.
Remembering things about family,
3.166
1
18
.092
friends, e.g., work, birthdays, address
Remembering things that have
happened recently

21.600

1

18

.000

Recalling conversations a few days later

21.600

1

18

.000

Remembering his/her address
and phone number

32.073

1

18

.000

(continued)
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Table 5. Test of Homogeneity of Variances (continued)
_____________________________________________________________________
Levene Statistic
df1
df2
Sig.
Remembering what day and month it is

.000

1

18

1.000

Remembering where things are usually kept 1.593

1

18

.223

Remembering where to find things when
placed differently

2.000

1

18

.174

Knowing how to work familiar machines

5.748

1

18

.028

Learning to use a new gadget or machine

3.168

1

18

.092

Learning new things in general

3.168

1

18

.092

Following a story in a book or on TV

.059

1

18

.811

Making decisions on everyday matters

3.168

1

18

.092

Handling money for shopping

6.923

1

18

.017

Handling financial matters e.g. the
pension, dealing with the bank

3.168

1

18

.092

Handling other everyday arithmetic
problems (how much food to buy).

.333

1

18

.571

5.748

1

18

.028

1.911

1

18

.184

Using his/her intelligence to understand
and to reason things through
Total Cognitive Symptoms

Notes: df1 = Degrees of freedom # 1; Sig. = significance or p-value
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Table 6
Descriptive for Total Cognitive Scores
_______________________________________________________________________
95% CI for M
N
M
SD
SE
LL
UL
Min
Max
Early onset
8 78.3750 2.77424
.98084
76.0557 80.6943 72.00 80.00
Late onset
12 75.7500 6.94295
2.00426
71.3387 80.1613 56.00 80.00
Total
20 76.8000 5.69949
1.27445
74.1326 79.4674 56.00 80.00
_______________________________________________________________________
Notes: N = Number in population; M = Mean; SD = standard deviation; SE = standard error; CI =
confidence interval; LL = lower limit; UL = upper limit; Min = minimum; Max = maximum

Table 7
Statistics for Total Behavioral Symptom Scores
________________________________________________________________________
95% CI for M
N
M
SD
SE
LL
UL
Min
Max
Early onset
8 19.2500 21.36586 7.55397 1.3877 37.1123
.00
69.00
Late onset
12 11.0833 11.85870 3.42331 3.5487 18.6180 2.00
45.00
Total
20 14.3500 16.32330 3.65000 6.7105 21.9895
.00
69.00
________________________________________________________________________
Notes: N = Number in population; M = Mean; SD = standard deviation; SE = standard
error; CI = confidence interval; LL = lower limit; UL = upper limit; Min = minimum;
Max = maximum
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Table 8
Analysis of Variance (Behavioral Symptoms)
_______________________________________________________________________
SS
df
MS
F
Sig.
Paranoid and Delusional

Between Groups
32.033 1
32.033
1.226 .283
Within Groups
470.167 18
26.120
Total
502.200 19
________________________________________________________________________
Hallucinations

Between Groups
2.133
1
2.133
.114 .739
Within Groups
336.417 18
18.690
Total
338.550 19
________________________________________________________________________
Activity Disturbances

Between Groups 19.200
1 19.200 5.858 .026
Within Groups
59.000 18
3.278
Total
78.200 19
________________________________________________________________________
Aggressiveness

Between Groups 10.800
1 10.800 2.113 .163
Within Groups
92.000
18
5.111
Total
102.800
19
________________________________________________________________________
Diurnal Rhythm Disturbance Between Groups
.008
1
.008
.014 .907
Within Groups
10.792
18
.600
Total
10.800
19
________________________________________________________________________
Affective Disturbances

Between Groups
.033
1
.033
.013 .909
Within Groups
44.917
18 2.495
Total
44.950
19
_______________________________________________________________________
Anxieties and Phobias

Between Groups
8.008
18
.008
.958 .341
Within Groups
150.542
18 8.363
Total
158.550
19
________________________________________________________________________
Note: SS = sum of squares; df = degrees of freedom; MS = mean squared; F = F-ratio
Sig. = p-value.
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Table 9
Test of Homogeneity of Variances for Behavioral Symptoms
________________________________________________________________
Levene Statistic

df1

df2

Sig.

1.189

1

18

.290

.628

1

18

.438

Activity Disturbances

2.775

1

18

.113

Aggressiveness

4.684

1

18

.044

Diurnal Rhythm Disturbance

2.449

1

18

.135

Affective Disturbances

.430

1

18

.520

Anxieties and Phobias

5.405

1

18

.032

Paranoid and Delusional
Hallucinations

________________________________________________________________
Notes: df1 = Degrees of freedom # 1; Sig. = significance or p-value

Table 10
Total Behavioral Symptom Scores
__________________________________________________________
SS
df
MS
F
Sig.
Between Groups
320.133
1
320.133
1.215 .285
Within Groups
4742.417
18
263.468
Total
5062.550
19
__________________________________________________________
Note: SS = sum of squares; df = degrees of freedom; MS = mean squared;
F = F-ratio; Sig. = p-value.
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Table 11
Test of Homogeneity of Variances of
Total Behavioral Symptom Scores
__________________________________
Levene Statistic
df1
df2
Sig.
.635
1
18
.436
__________________________________
Notes: df1 = degrees of freedom #1; Sig. = p-value
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Evidence of Trustworthiness
The qualitative component of this research study utilized and followed proven
procedures, the six-phase thematic analysis (Braun & Clarke, 2006) and grounded theory
(Patton, 2002). This researcher reported a step-by-step approach in the previous
qualitative component section. This section explained all codes and phrases that emerged
from re-reading audio-taped, qualitative interviews. Finally, primary and sub-themes
were presented including examples and extracts as supporting evidence. Reliability of
themes was checked against each caregiver participant’s Microsoft Word-typed written,
audio-taped report for accuracy and confirmation. Validity was obtained by comparing
codes and themes against the quantitative database used in SPSS that arose out of
questionnaire responses from caregiver participants.
The quantitative component of this research study used the BEHAVE-AD
informant survey that has been successfully used by various researchers. It has good
reliability in discriminating and good validation in AD cases (Reisberg et al., 2014;
Robert et al, 2010). The BEHAVE-AD questionnaire is an informant-based rating scale
that assesses behavioral symptoms in AD patients, independent of comparatively difficult
to treat cognitive symptoms. It was chosen because it is an informant-based rating scale
and was developed to elicit information obtained from caregiver reports. In addition to
the BEHAVE-AD instrument used to measure behavioral symptoms, the Short-IQCODE
questionnaire was chosen because it has been proven to be useful for individuals who are
unable to undergo direct-cognitive testing due to acute illness, lack of cooperation, or
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death. This instrument measures a single general factor of cognitive decline and validly
reflects past cognitive decline. Researchers have compared the Short-IQCODE to neuropathological diagnosis (Rockwood et al., 1998; Thomas et al., 1994) and it has been
significantly correlated with amyloid precursor protein in AD patient’s blood (Thomas,
1996). Both the BEHAVE-AD and Short-IQCODE overall scores (dependent variables)
reported by caregiver participants were inputted into the SPSS program, using the oneway ANOVA to analyze groups (EOAD and LOAD). This revealed synthesis of evidence
that was similar to both qualitative and quantitative outcomes.
Summary
The purpose of this mixed-method study was to determine whether or not
individuals with EOAD vs. LOAD experience different behavioral and cognitive
(memory) symptoms. Caregiver participants were used as informants on behalf of AD
patients. Research questions included RQ1(Are there differences in cognitive symptoms
between EOAD patients and LOAD patients?) and RQ2 (Are there behavioral between
EOAD patients and LOAD patients?).
Participants/informants were recruited from various caregiver support group
facilities throughout the Houston metropolitan and surrounding areas. Most of the
participants were members of the Alzheimer’s Association’s Houston Southeast Chapter.
The specific criteria requirements included: Must be 18 years of age or older; caring for
an individual who had been diagnosed with early-onset AD (EOAD)/late-onset AD
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(LOAD); diagnosis had to be in accordance with criteria in the Diagnostic and Statistical
Manual of Mental Disorders, Fifth Edition – DSM-V (APA, 2013).
Demographic samples and data collection were between October 12, 2015 and
March 16, 2016. Caregiver participants were divided into two groups (EOAD and
LOAD) and were given instruments to measure both cognitive and behavioral symptoms.
Consent forms were provided and discussed and signatures were not obtained until
understanding of the study was indicated by all participants. Six participants were
included in the qualitative data collection process of the study. Twenty participants were
included in the quantitative component of the study. Qualitative caregiver participants
were given demographic background surveys to fill out; and they were audio-taped in
person, with the researcher using two open-ended, semi-structured interview questions.
These interview questions were transcribed in Microsoft word verbatim. The quantitative
data collection process of the study consisted of participants filling out packets face-toface, over the phone, or via the internet. All face-to-face interviews (qualitative and
quantitative) were conducted in library conference rooms, private offices, and in
participants’ homes.
Results of the qualitative component of the study were presented in Table 2 with
several primary themes: 1) cognitive impairment; 2) mood swings; 3) impulsiveness; 4)
struggles with activities of daily living (ADLs); 5) psychological behaviors; and 6)
maladaptive (adverse) behaviors. According to caregiver participants, 100% of caregiver
recipients experienced cognitive impairment, specifically short-term memory loss. This
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was also true for psychological behaviors. It was reported that 6 out of 6 of the caregiver
recipients went through periods when they experienced anxiousness, agitation, irritability,
frustration, depression, paranoia, and hallucinations, depending on the present state of the
disease.
Results of the quantitative component indicated that (RQ1) there were no
statistically significant differences in total cognitive symptom scores between EOAD and
LOAD groups, F (1, 18) = 1.019, p = .326, 2 = 0.05. Results for RQ2 indicated that
there were no statistically significant differences in behavioral symptom scores between
EOAD and LOAD groups, F (1, 18) = 1.215, p = .285, 2= 0.06. Findings, limitations,
and recommendations will be discussed in Chapter 5.
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Chapter 5: Findings, Limitations, and Recommendations
Introduction
The purpose of this study was to explore Alzheimer’s disease, specifically earlyonset AD (EOAD) versus late-onset AD (LOAD) in individuals, and determine whether
there are differences or similarities among behavioral and cognitive symptoms between
these two groups. I used a mixed-method approach and caregiver participants were used
as informants on behalf of EOAD and LOAD patients to answer research questions. In
this chapter, I provided discussions and findings presented in Chapter 4. In addition, I
will discuss the limitations of the current study and recommendations for future research.
Finally, I will offer implications for social change.
Interpretation of the Findings
Qualitative Findings
Two themes that emerged from qualitative data analysis using grounded theory
and thematic analysis were cognitive impairment and psychological behaviors. When it
came to cognition, the majority of caregiver participants indicated that care recipients
suffered from lack of short-term memory. When it came to behavioral observations, the
majority of caregiver participants indicated that care recipients suffered from
psychological disturbances that included anxiety, agitation, irritability, frustration,
depression, paranoia, and hallucinations. This was supported by the narratives they
provided to the qualitative interview question: Over the past 2 – 5 years, what are some
of the things you observed about this person’s change in memory/behavior?
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Activities of daily living and maladaptive behaviors were two themes that the
majority of caregiver participants found to be the most challenging to witness or
experience the care recipient going through. This was supported by the narratives they
provided to the qualitative interview question: What are some of the most
favorable/unfavorable moments you have observed about this individual’s
memory/behavioral changes?
Quantitative Findings
Research Question 1 was used to assess if EOAD patients have different
cognitive symptoms than LOAD patients. There was insufficient evidence to reject the
null hypothesis. EOAD patients have the same cognitive symptoms as LOAD patients.
Total caregiver recipients (N = 20) were divided into two groups: EOAD caregiver
recipients (n = 8) and LOAD caregiver recipients (n = 12). Mean score for EOAD was
78.3750 (SD = 2.77) and mean score for LOAD was 75.75 (SD = 6.94). Total cognitive
scores for EOAD had a range from 72 – 90 and cognitive scores for LOAD had a range
from 56 – 80, indicating lower cognitive scores than the counterpart. This was supported
by questionnaire responses to the Short-IQCODE by caregiver participants.
Research question 2 was used to determine if EOAD patients have different
behavioral symptoms than LOAD patients. There was insufficient evidence to reject the
null hypothesis. EOAD patients have the same behavioral symptoms as LOAD patients.
Total caregiver recipients (N = 20) were divided into two groups: EOAD caregiver
recipients (n = 8) and LOAD caregiver recipients (n = 12). Mean score for EOAD was
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19.25 (SD = 21.37) and mean score for LOAD was 11.08 (SD = 11.86). Total behavioral
scores for EOAD had a range from 0 – 69 and behavioral scores for LOAD had a range
from 2 – 45. The maximum EOAD total behavioral score was 69 and the maximum
LOAD total behavioral score was 45, indicating lower behavioral scores for LOAD
caregiver recipients. This was supported by questionnaire responses to the BEHAVE-AD
informant instrument provided by caregiver participants.
Summary of Findings
Research studies indicate that AD is characterized by the onset of impairments in
memory and executive function, in addition to cognitive and behavioral problems such as
depression, apathy, and agitation (Wilson, Arnold, Beck, Bienias, & Bennett, 2008).
Previous studies also indicated that not everyone who develops the disease will have the
exact same symptoms, or the same rate of progression (AA, 2013).
In this study, both groups of caregiver participants, whether they cared for an
individual who had been diagnosed before the age of 65 (EOAD) or after the age of 65
(LOAD), all agreed that when it came to cognitive symptoms, care recipients showed a
decline in memory as the disease progressed. However, when it came to behavioral
symptoms, care recipients exhibited different behavioral symptoms at different stages of
the disease. In other words, progression of behavioral symptoms did not happen in a
linear pattern/sequence. Each stage of the disease can have different symptoms or
sometimes the stages will overlap (AA, 2013).
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The demographic background and characteristics of the study included 35% of
men and 65% of women, with 74.5 years being the mean age of participants. Consistent
risk factors for AD are age and sex (Kalaria et al., 2008; Perez et al., 2012). Prevalence
studies such as the Chicago Health and Aging Project (CHAP) and the aging
Demographics and Memory Study (ADAMS) revealed that about two-thirds of
Americans with AD are women. Of the 5.2 million Americans older than 65 years with
AD, 3.4 million are women and 1.8 million are men.
Limitations
Limitations of the study included recruitment of participants, location of
Alzheimer’s caregiver support groups, and race/ethnic backgrounds. The participants in
the study were recruited from various support groups that included members from the
Alzheimer’s Association. Due to time and cost constraints, the quantitative sample size
(N=20) of the study was small. The locations of the support groups were throughout the
Houston metropolitan area and surrounding cities and towns. Participants were recruited
from the Houston Southeast Chapter of the Alzheimer’s Association. As a result, it is not
possible to generalize the findings of this study to other Alzheimer’s caregiver support
groups outside of the Houston and surrounding areas or chapters of the Alzheimer’s
Association outside of Houston or the United States.
This study consisted of 40% Black/African American; 5% Hispanic/Latino; and
55% White/Caucasian participants. Therefore, generalizing this study to other
races/ethnicities should be carefully considered.
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Recommendations
In future studies it would perhaps be more beneficial to interview a larger number
of caregiver participants, which would bring about a higher number of care recipients in
regards to races/ethnicities, socioeconomic backgrounds, as well as to include different
areas in the United States and other countries. Collaboration with previous, present, and
future researchers could perhaps build on this study. Consistency of successful outcomes
could result in better protocols and better planning and treatment for AD clients and/or
patients. Then, perhaps, such a study could be generalized to larger populations in regard
to culture, race, socio-economic, states, and countries.
Stage was also a factor in both cognitive and behavioral symptoms. It would be
beneficial to have care recipients evaluated regularly with the BEHAVE-AD and the
Short-IQCODE. These instruments could be used by psychiatrists, psychologists and
other clinicians to assess cognitive and behavioral symptoms at each stage of Alzheimer’s
disease. Whether or not the client or patient has been diagnosed with EOAD or LOAD,
the fact still remains that these symptoms are present and are indications that there is a
need for better treatment planning and prevention.
Implications for Social Change
Continual use of caregiver participants for future studies can ensure that care
recipients, whether they have been diagnosed at EO AD or LOAD, have a voice. Many
care recipients in this study were affected by cognitive impairment, i.e., short-term
memory loss and aphasia, which appeared to get worse as the disease progressed. Quality
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of life for these individuals could be improved through use of cognitive and behavioral
measures instituted regularly before and after disease progression.
Behavioral and cognitive charts can be created by various facilities and given to
caregivers to be used from one month to the next. On a monthly basis, on behalf of their
care recipients, caregivers could then pass these charts on to treating private-care
physicians, psychiatrists, psychologists, and/or clinicians. This process would give the
treating staff an idea of what cognitive decline or behavioral disturbances care recipient
have experienced over the past month. This protocol or particular instrument could be
used as standard of care procedures for all patients with AD. This extra information
would be provided by care recipients/caregivers along with personal backgrounds, biopsychosocial history, and medical records when visiting their treating clinicians in private
practices, hospitals, community emergency centers, nursing homes, or residential
homes/facilities. This standard of care procedure could ensure a more accurate
assessment of the patient, resulting in better diagnosis, treatment, preventative measures
and successful outcomes.
Conclusion
This mixed-method study was conducted in order to fill a gap in research by using
sequential use of a qualitative component and materials, followed by a quantitative
component and materials. Caregiver participants were used as informants and gave their
responses/perspectives on cognitive and behavioral symptoms that they observed in EOAD
and LOAD care recipients. Once the data collection phase of the study was complete, I
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called each participant via phone and went over interviews, questionnaires, and
demographic surveys to ensure the accuracy of the information. I determined that there
were no significant variable differences between EOAD and LOAD caregiver recipients.
Caregiver participants (N = 6) were interviewed and asked to give personal
perspectives of what they observed in the EOAD (n = 3) and LOAD (n = 3) care recipients
they had cared for in the last 2 – 5 years. Two themes that emerged from the qualitative
portion of the study were: cognitive impairment and psychological behaviors. Caregiver
participants indicated that care recipients suffered from lack of short-term memory and
psychological disturbances such as anxiety, agitation, irritability, frustration, depression,
paranoia, and hallucinations.
Caregiver participants (N = 20) were asked to fill out survey questions (BEHAVE
– AD and Short IQCODE). Through the quantitative portion of the study, I determined
that there were no significant variable differences (cognitive/behavioral symptoms)
between EOAD (n = 8) and LOAD (n = 12) caregiver recipients. In other words, results
revealed that individuals with AD have the same cognitive and behavioral symptoms
whether they have an early onset or a late onset of the disease (Wilson, Arnold, Beck,
Bienias, & Bennett, 2008). However, previous studies have indicated that not everyone
who develops the disease will have the exact symptoms, or the same rate of progression
(AA, 2013).
When both qualitative and quantitative results were combined, it was determined
that there were no differences in cognitive symptoms (cognitive impairment, mood swings,
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impulsivity, struggles with ADLs), or behavioral symptoms (psychological behaviors,
maladaptive behaviors), whether experienced by EOAD or LOAD care recipients. The
cognitive/behavioral symptoms may have been experienced at different stages of the
disease; however, the same symptoms were present.
During the collection phase of this study, many of the participants discussed their
loved one’s cognitive impairments and psychological behaviors. It did not matter whether
the individual was in their early 50’s and 60’s or in their later 70’s or 80’s. Race, gender,
socioeconomic status, education, religion, or sexual orientation did not impact these
impairments or behaviors. Reisberg et al. (2014) suggested that cognition-based symptoms
of AD occur universally and progressively with the advance of AD and that behavioral
symptoms of AD are not progressive, but peak at some stage prior to the final stage of the
disease.
Age and gender continue to be risk factors for AD (Kalaria et al, 2008; Perez et
al., 2012). The Chicago Health and Aging project (CHAP) and the Aging Demographics
and Memory Study (ADAMS) are prevalence studies that revealed that about two-thirds of
Americans with AD are women. Of the 5.2 million Americans older than 65 years of age
with AD, 3.4 million are women and 1.8 million are men. Baby-boomers continue to age
and the majority will be women according to various studies on Alzheimer’s disease (AA,
2013; Kalaria et al., 2008; Perez et al., 2012). This disease is still one of the top ten causes
of death in the United States and the fifth leading cause of death among Americans over
the age of 65 (AA, 2015). This fatal disease is a neurodegenerative brain disorder of
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unknown cause with neuropathological and neurochemical features. It is usually insidious
in onset and increases slowly, but steadily. After diagnosis, individuals with the disease
can live as long as 8 to 20 years (AA, 2013). Unfortunately, there still remains no known
cure for AD.
This study has certain strengths as well as limitations. In order to reduce selection
bias, participants recruited were from member facilities that belong to the Alzheimer
Association. In addition, inclusion criterion for diagnosis for AD was used according to
the DSM-V (APA, 2013). Caregiver roles were that of informants for caregiver recipients
who had AD—given the fact that some individuals with AD are not always cognitively
capable, as a result, informants were a positive alternative. Behavioral and cognitive
instruments (BEHAVE-AD and Short IQCODE) were tools utilized by all participants
and scored by a statistical software program (SPSS). However, these tools are subjective,
as well as the perspective of caregivers when it comes to being sensitive enough to
answer the question or differences in cognitive or behavioral symptoms. Therefore, a
future study is warranted to possibly assess AD clients more objectively.
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Appendix A: DSM-V Criteria for Major or Mild Neurocognitive Disorder due to
Alzheimer’s disease
A. The criteria are met for major or mild neurocognitive disorder.
B. There is insidious onset and gradual progression of impairment in one or more
cognitive domains (for major neurocognitive disorder, at least two domains must be
impaired).
C. Criteria are met for either probable or possible Alzheimer’s disease as follows:
For major neurocognitive disorder:
Probable Alzheimer’s disease is diagnosed if either of the following is present;
otherwise, possible Alzheimer’s disease should be diagnosed.
1. Evidence of a causative AD genetic mutation from family history or genetic
testing.
2. All three of the following are present:
a. Clear evidence of decline in memory and learning and at least one other
cognitive domain (based on detailed history or serial neuropsychological
testing).
b. Steadily progressive, gradual decline in cognition, without extended
plateaus.
c. No evidence of mixed etiology (i.e., absence of other neurodegenerative
or cerebrovascular disease, or another neurological, mental, or systemic
disease or condition likely contributing to cognitive decline).
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For mild neurocognitive disorder:
Probable Alzheimer’s disease is diagnosed if there is evidence of a causative
Alzheimer’s disease genetic mutation from either genetic testing or family
history.
Possible Alzheimer’s disease is diagnosed if there is no evidence of a causative
Alzheimer’s disease genetic mutation from either genetic testing or family
history, and all three of the following are present:
1. Clear evidence of decline in memory and learning
2. Steadily progressive, gradual decline in cognition, without extended plateaus.
3. No evidence of mixed etiology (i.e., absence of other neurodegenerative or
cerebrovascular disease, or another neurological or systemic disease or
condition likely contributing to cognitive decline).
D. The disturbance is not better explained by cerebrovascular disease, another
neurodegenerative disease, the effects of a substance, or another mental, neurological, or
systemic disorder.
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Appendix B: Stages and Symptoms of AD
Stage 1: The No Impairment stage of AD is also known as normal functioning,
which is associated with having no memory problems. An individual visiting his or her
medical professional would not show any evidence of dementia (Dowling, Hermann, La
Rue, & Sager, 2010).
Stage 2: The Very Mild Cognitive Decline stage of AD is also known as normal
age-related changes in an individual. This individual will have memory lapses, i.e.,
forgetting certain words, or where they have put daily objects. But, when interviewed by
medical professionals, family members or friends, they will not show any dementia
symptoms (Wilson et al., 2008).
Stage 3: Mild Cognitive Decline stage of AD is also referred to as the early-stage
AD--some can be diagnosed with symptoms, but not all. At this stage of the disease,
individuals may have problems with memory and concentration. Family members,
friends, or medical professionals will start to notice the individual having difficulty
remembering names, performing tasks at work or at home, misplacing valuables, or
having increased difficulty planning and organizing events or materials (Wilson et al.,
2008).
Encoding, storage, and retrieval are three stages of memory operations (Sternberg,
2009). Therefore, studying memory impairment can give significant insight to cognitive
dysfunction, which limits autonomy in complex activities performed by those in the early
dementia stages. Mild cognitive decline, also mild cognitive impairment (MCI) is

133
abnormal cognitive functioning in older adults without the presence of dementia (Rueda
& Schmitter-Edgecombe, 2009; Van Damme, Belanger, & Belleville, 2009; Ward et al.,
2013; Wilson et al, 2008). MCI is associated with an increased possibility of suffering
from AD. However, 40 percent of those who suffer from MCI will not necessarily
develop AD--but examining profiles of MCI cases can often determine which ones will
develop AD and which ones will not (Pike, Moss, Rowe, & Savage, 2008; SchmitterEdgecombe, Greeley, & Woo, 2009).
Stage 4: Very Moderate Decline stage of AD is also known as the mild or earlystage of AD. A medical interview can detect individual symptoms in the areas of
forgetfulness, impairment in counting numbers or arithmetic, difficulty in paying bills or
keeping up with finances, and becoming withdrawn or moody in social situations (AA,
2013).
Stage 5: The Moderate Severe Cognitive Decline stage is also known as the
moderate or mid-stage of AD. At this stage of AD, individuals can still feed themselves
and go to the bathroom alone. They also remember family members and friends. The
daily activities that may become difficult include recalling addresses, remembering dates,
and choosing the proper clothing for the proper seasons or occasions (Gauthier &
Molinuevo, 2013).
Stage 6: Severe Cognitive Decline is also known as the moderately severe or midstage of AD. Patients/individuals at this stage have significant memory loss with
considerable personality change. Clients/individuals become unaware of their
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surroundings, may have problems remembering spouse or caregivers’ names, or need
assistance with putting on their clothes, e.g., may put pajamas over their daytime clothes
or put their shoes on the wrong feet. In addition, at this stage of AD, the client can
become suspicious of his caregiver or spouse motives, due to the client’s personality or
behavioral changes. It is also common for individuals at this stage of AD to experience
change in sleep patterns and they are subject to wander if they are not supervised
properly (AA, 2013).
Stage 7: Very Severe Cognitive Decline can also be known as the Severe or latestage of AD. Reisberg (2013) explains that patients at this stage of the disease will
become totally dependent on others to help with daily activities of living. They are unable
to hold their heads up, to use the bathroom or eat without the assistance of a caregiver. In
addition, these patients cannot respond to their environment. They are no longer able to
carry on a normal conversation with others. They may say a few words or phrases. They
can no longer swallow, their reflexes become abnormal, and they can no longer smile or
move certain body muscles (Gauthier & Molinuevo, 2013).

135
Appendix C: Cooperation Email
Email of Cooperation from Alzheimer’s Association (Houston Southeast Chapter)
Mon, Oct 14, 2013 10:19 am

Re:

Prospectus on Alzheimer's Disease

We at the Alzheimer's Association know the value that research can bring to expanding
our understanding of Alzheimer's disease and the caregiver experience. For that reason,
we are happy to assist you with accessing care partners through our chapter's programs
and services.
What we can offer is this... We serve persons with early stage Alzheimer's disease and
their care partners through our Early Stage programs. Of particular interest to you may be
our Learning Together and Discovering Connections groups. These groups serve persons
with dementia and their care partners by providing education and/or engaging
programming, followed by separate support groups for PWD and care partners.
Through those early stage programs you could have access to approximately 15 - 20 care
partners. In addition, we offer a wide variety of community-based early stage programs
for which we have a mailing list of about 100 couples. You could have access to
interested parties from that list, as well.
In addition, we sponsor about 50 caregiver support groups throughout our 37-county
region. Those groups meet monthly and we could help you gain access to those
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caregivers/groups via email/snail mail introduction. Typically about 250 - 350 persons
participate in support groups each month.
Here's a link to the various support groups we run, just to give you an idea of their
locations. http://www.alz.org/documents/tex/support_groupsseptember2013.pdf
Let me know what you think about the type of access and the types of folks you could
speak with through our chapter's services.
Best,
It was nice speaking with you over the phone yesterday. Attached is my prospectus on
Alzheimer's disease. I have completed the prospectus and Chapter 2: Literature Review
of my dissertation. I am now working on the Introduction, which is Chapter 1 of the
dissertation.
It is policy that I finish Chapter 3: Methodology section in addition to Chapters 1 and 2 of
the dissertation in order to get IRB approval from my school. This is why I am contacting
you at this point because, I would like you to be able to determine what information you
have available that could benefit my research on the subject of caregivers and what
information they can provide on the symptoms and stages of the AD patients that they
care for and observe on a daily or routine basis. Of course, I would not be able to collect
data until Chapters 1, 2, & 3 of my dissertation has been approved by the IRB. However,
I am trying to plan ahead by contacting you to give you the attached prospectus in order
for you to decide if we could be of service to each other. If you agree, I would need to
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receive a letter of intent from you/your organization indicating such--I have form letters
that I can send you as well.
I hope this will be the start of a long relationship, especially working on ways to slow the
progression or cease the disease, AD, all together.
Note: I am a doctoral student of clinical psychology at Walden University. I am also
doing my internship at a private practice in Missouri City/Sugar Land, Texas--my predoctoral year ends on December 9, 2013 and I plan to continue my dissertation course
through February 2013. I conduct psychotherapy with individuals from age 5 years old to
78 years old. In addition, I conduct psychological evaluations on adults and child and
adolescents throughout the week except Thursdays at Ashar Counseling and
Psychological Services. On Friday mornings from 9:30 AM to 11:30 AM, I attend
training at Charis Psychological Services in the Gessner/Beechnut Area.
Regards,
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Appendix D: Demographic Questionnaire
1. Do you (caregiver) speak English? ______yes ______ no
2. What is AD patient age? __________
3. What is AD patient gender? Male___ Female____ Other____
4. What is AD patient race/ethnicity?
a. Asian American
b. Black/African American
c. Hispanic/Latino
d. Native American
e. White/Caucasian
f. Other _______________________

5. AD patient Marital Status:
a. Single
b. Married
c. Separated
d. Divorced
e. Widowed

6. AD patient highest level of education:
a. GED
b. High school
c. Some college
d. College graduate
e. Post graduate studies
f. Post graduate degree
7. Economic ($) Status of AD Patient:
a. 1 to 19,999
b. 20,000 to 49,999
c. 50,000 to 69,999
d. 70,000 to 99,999
e. 100,000 and above
8. Are you the primary caregiver (provide day to day care)? Yes_______ No________
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9. What is your relationship to the care recipient?
a. Spouse
b. Adult Child/Grandchild
c. Other _______________________

10. How long have you been a caregiver to AD patient? Year(s)____ Month(s)____.
11. Approximate hours/day provided to AD patient? _____
12. What age was patient when he/she was diagnosed with AD: Less than 65 years
old?____ or More than 65 years old?____
13. Patient’s stage of AD (AA, 2013). Choose from the following by circling the correct
letter:
a. Stage 1 (No Impairment/Normal functioning).
b. Stage 2 (Very Mild Cognitive Decline -- Normal age related changes--forgetting
certain words, forget where they put things, no dementia problems).
c. Stage 3 (Early stage of AD/Mild Cognitive Decline -- memory problems, loss of
concentration, difficulty remembering names, cannot perform tasks at home or at work,
problems planning and organizing events or materials).
d. Stage 4 (Very Moderate Decline/Mild or Early Stage -- forgetfulness, impairment in
counting or arithmetic, difficulty in paying bills or keeping up with finances, becomes
moody or withdrawn in social situations).
e. Stage 5 (Moderate Severe Cognitive Decline/Moderate or Mid-Stage of Ad -- can feed
themselves, go to the bathroom alone, remember family and friends, problems with
recalling addresses, dates, choosing right clothing for the proper seasons or occasions).
f. Stage 6 (Severe Cognitive Decline/Moderately Severe or Mid-Stage of AD -significant memory loss, personality/behavioral change, is unaware of environment,
problems remembering caregiver or spouse’s name, need assistance putting on clothes-may put shoes on wrong feet or may put pajamas on over their clothes, becomes
paranoid/suspicious of caregiver motives, change in sleep pattern, patient may wander off
if not supervised properly).
g. Stage 7 (Very Severe Cognitive Decline/Severe or Late-Stage of AD -- patient is
totally dependent on caregiver to help with activities of daily living, need assistance with
holding their heads up, eating, and using the bathroom; cannot respond to their
environment, can only say a few words, can no longer hold a conversation with others,
can no longer swallow, they do not have the use of their muscles, reflexes are abnormal,
and possibly death occurs).
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Appendix E: Behavioral Pathology in Alzheimer’s Disease
(BEHAVE-AD)
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Copyright © 1986 by Barry Risberg, M.D. (all rights reserved).
The BEHAVE-AD has been “reproduced with permission.”
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Appendix F: Short IQCODE
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Appendix G: Qualitative Interview
1. Over the past 2 – 5 years, what are some of the things you observed about this
person’s change in memory/behavior?
a. Can you elaborate on his/her memory when it comes to their spouse,
significant other, family, friends? How does he/she react to them?
b. Can you elaborate on his/her memory when it comes to family and
friends’ addresses, birthdays, occupations, etc.? What are her actions?
c. What are some of the things that he/she does that make you know that she
remembers or forgets the time, date, and place? How does he/she behave if
they can or can’t remember?
d. What about when it comes to remembering how to work a particular
machine/gadget around the house? How does he/she react if they can or
can’t remember?
e. How does he/she react to handling money or financial situations?
f. What about making normal day-to-day decisions (what to eat, what to
wear, when to use bathroom, when to brush teeth)? What are some of the
ways she reacts to these activities?
g. Learning new things in general? How does he/she react?
h. Remembering events that happened the day before? If they can remember,
how do they react/if they can’t remember, how do they react?
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2. What are some of the most favorable moments you have observed about this
individuals memory/behavioral changes? What are some of the most unfavorable?
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Appendix H: Permission to use BEHAVE-AD Instrument
I would be pleased to provide you with permission to use the BEHAVE-AD in your
research in the Clinical Psychology Program at Walden University in association with
your dissertation and with the publication of the dissertation provided that you agree to
the following conditions:
My conditions are that the scale is properly referenced and that the copyright is noted in
all reproductions.
The complete reference for the BEHAVE-AD is:
Reisberg, B., Borenstein, J., Salob, S.P., Ferris, S.H., Franssen, E., Georgotas, A.
Behavioral symptoms in Alzheimer's disease: Phenomenology and treatment.Journal of
Clinical Psychiatry, 1987, 48 (5, suppl.): 9-15.
The copyright notice for the BEHAVE-AD is as follows:
Copyright ©1986 by Barry Reisberg, M.D., all rights reserved.
You should also note that the scale has been "reproduced with permission."
This permission will extend for a period of 8 years after you reply agreeing to the above
conditions.
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Sent: Tuesday, March 10, 2015 7:11 PM
Subject: Permission Request
Thank you for returning my call on Tuesday, March 10, 2015 in regards to my request to
have written permission to include your BEHAVE-AD tool in my dissertation.
I am a doctoral student in the clinical psychology program at Walden University. My
dissertation is on Alzheimer's disease and I am comparing early-onset AD patient
symptoms to late-onset AD patient symptoms using caregivers as informants. Your
Behavioral pathology in Alzheimer's Disease (BEHAVE-AD) tool will be used to
measure behavioral symptoms and I will be using the Short Form of the Informant
Questionnaire on Cognitive Decline in the Elderly (Short IQCODE) to measure cognitive
symptoms. My research question is: Are there differences in symptomology between
EOAD patients and LOAD patients?
In addition to using the BEHAVE-AD as a measuring tool, once my research is complete,
Walden University will be publishing it as an appendix at the end of my dissertation.
I hope to hear from you soon.
Thanking you in advance,
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Appendix I: Email to/Acknowledgment (Use of Short IQCODE)
Subject: RE: Short IQCODE use in dissertation study
Date: Tue, Aug 18, 2015 8:00 pm

Thanks for letting me know about your project. Best wishes for it.
Regards
______________________________________________________________________________
Sent: Wednesday, 19 August 2015 10:51 AM
Subject: Short IQCODE use in dissertation study
I am a graduate student at Walden University in the Doctoral Clinical Psychology Program
(United States). My dissertation topic is "Comparative memory/behavioral symptoms of
Alzheimer's disease: EOAD vs LOAD."
This email is to inform you of my plan to use your instrument the Short Form of the Informant
Questionnaire on Cognitive Decline in the Elderly (Short IQCODE) as a tool to obtain information
from potential participants (caregivers to Alzheimer patients/victims) for my dissertation research.
I would like to thank you for creating the Short IQCODE, it is an asset greatly appreciated that
will enable me to conduct my research study. If you have any questions or concerns, please do
not hesitate to contact me at the email or telephone number below.

Regards,
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Appendix J: Protecting Human Research Participants
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Appendix K: Flyer

Opportunity to be a participant in a dissertation
study if
YOU are over 18 and a CAREGIVER to
SOMEONE who is one of the following:
 Diagnosed with Alzheimer’s disease before
65 years old (Early onset AD) or
 Diagnosed with Alzheimer’s disease after 65
years old or later (Late onset AD)
♦♦♦♦♦♦♦♦♦

